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1. INTRODUCTION
The   treatment  of  acute  diseases  or  a  chronic  illness  has  been  mostly  accomplished  by
delivery of drugs to patients using various pharmaceutical dosage forms including tablets,
capsules,  pills, suppositories,  creams, ointments,  liquids,  aerosols,  and injectables as drug
carriers1. Drugs may be administered by variety of routes but oral administration is adopted
wherever possible. There are many applications and large markets for non-oral products and
the technologies that deliver them. However, if it is an applicable option, oral drug delivery
will be selected in all but the most exceptional circumstances. It is safest, easiest, and most
economical route of drug administration. Amongst drugs that are administered orally solid
oral dosage forms i.e. tablets and capsules, represent the preferred class of products. Out of
the two oral solid dosage forms, the tablets have number of advantages like tamper proof, low
cost  and  speed  of  manufacturing  (direct  compression),  ease  of  administration,  patient
compliance and flexibility in formulation etc.
1.1. Conventional Drug Therapy:
This  requires  periodic   doses  of  therapeutic  agents.  These  agents  are  formulated  to
produce  maximum activity,  stability  and  bioavailability.  for  most  drugs,  conventional
methods of  drug  administration  are effective, but some drugs are unstable  or  toxic and
have narrow therapeutic index. some drugs posses solubility problem. conventional forms
often cause problems to the patient, they maintain the therapeutic drug level for only short
duration. this gives rise to sharp fluctuation of drug levels in plasma and tissue.
      Disadvantages of conventional drug delivery system:
 In this system there is very less or no control over the release of the drug and 
effective concentration at the target site can be achieved by intermittent of    
excessive doses.
 The extent and rate of absortion of drug from conventional formulations may vary 
greatly, depending on the factors such as physio chemical properties of the drug 
presence of excipients ,various physiological factors such as the the presence or 
absence of food.  pH of the gastro intestinal motility.3
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 Care ful calculation necessary to prevent over dosing.
 The dosing pattern in conventional dosage forms results in constantly changing, 
unpredictable and often sub-therapeutic concentration, leading to marked side 
effects in some cases.
1.2. Modified  Drug Delivery System: 4,5,6
Modified release DDS include systems with pH–dependent, extended, delayed or pulsed drug
release.  sustained,  extended  or  prolonged  release  drug  delivery  systems  are  terms  used
synonymously to describe this group of controlled drug delivery.
Classification: 
The USP and NF has defined a modified release dosage forms as one in which the drug
release  characteristics  of  time  course  and  location  are  chosen  to  accomplish  therapeutic
objectives not offered by conventional dosage forms.
Sustained Release:   A sustained-release dosage form is designed to achieve a prolonged
therapeutic effect by continuously releasing medication over an extended period of time after
administration of a single dose. These systems try to mimic zero-order release by providing
drug in a slow first-order fashion.
Controlled  release: The  term  “Controlled  release”  has  become  associated  with  those
systems from which therapeutic agents may be automatically delivered at predefined rates
over a long period of time. These systems deliver drugs in a zero-order fashion.
Repeat Action:  Alternative method of sustained release in which multiple doses of a drug
are contained within a dosage form and each dose is released at a periodic interval.
Site-specific and receptor targeting: drug to the particular organ or tissue of the body. For 
receptor release, target is particular receptor for a drug within an organ or tissue.       
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Fig.1 - Drug level versus time profile showing differences between zero-order controlled
release;  slow first-order sustained release,  and release form a conventional tablet or
capsule.
1.3. Delayed Release Systems
     The design of such system involves release of drugs only at a site in the gastrointestinal 
tract. The drugs contained in such a system are those that are:                                                    
i)          Destroyed in the stomach or by intestinal enzymes
ii)         Known to cause gastric distress
iii)        Absorbed from a specific intestinal site or
iv)        Meant to exert local effect at a specific gastrointestinal site.
The two types of delayed release systems are:
 Intestinal release systems: A drug may be enteric coated for intestinal release for 
several known reasons such as to prevent gastric irritation, prevent destabilization in 
gastric pH  etc.
   Colonic release systems: Drugs are poorly absorbed through colon but may be      
delivered to such a site for two reasons.  
                        a) Local action in the treatment of ulcerative colitis
                        b) Systemic absorption of protein and peptide drugs
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Advantage is taken of the fact that pH sensitive bioerodible  polymers like polymethacrylates
release the medicament only at the alkaline pH of colon or use of divinylbenzene cross-linked
polymers that can be cleaved only by the azo reductase of colonic bacteria to release free
drug for local effect or systemic absorption.
1.4. Delayed  Release  Solid oral Dosage Forms:
The correct selection and balance of excipients and processes in solid dosage formulations
are designed either for improving the micrometric or macrometric proprerties of materials
during manufacture and for providing a desired drug delivery system.7 the most commonly
used  pharmaceutical  delayed  release  solid  dosage  forms today include  tablets,  capsules,
granules, pellets.
                                                                         
 
       Fig .2 - RelationShip of Pharmaceutical Delayed Release Solid Dosage Forms
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1.4.1. Classification of Delayed Release Solid Oral Dosage Forms:
  Delayed release solid oral  dosage forms are  available  either  as  single unit(non divided
formulations–tablets,  capsules)  or  as  multiple  unit  (divide  formulations-pellets,  mini
-tablets)forms.
1.4.1.1.  Single  unit dosage forms:
The single-unit  dosage  forms usually refer  to  diffusion controlled systems which include
monolithic systems.where the diffusion of a drug through a matrix is the rate limiting step
reservoir or multilayered matrix systems,8 where the diffusion of the drug through polymer
coating or layer of the system is the rate limiting step. However , generally, release of drugs
will occur by a mixture of these two mechanisms.
1.4.1.2.  Multi unit dosage forms: 9,10
 Types of multi unit dosage forms comprise :
 Granules
 Pellets
 Microparticles (microspheres ormicrocapsules ) and  Nano particles.  
 Mini  tablets  and  minidepots  (dispersed  and  distributed  through  out  the
gastro intestinal tract when the capsule or tablet disintegrates).  
 Multi unit tablets (divided at ingestion with out loss of the depot effect, as the sub unit
act as a self contained depots).
1.4.1.3. Therapeutic Advantage of Multi units over single units:
When taken orally ,multi unit dosage forms
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 Disperse freely in the gastro intestinal tract.
 Provides less risk of dose dumping.
 Reduces localized concentration of irritative drugs.
 Reduce risk of inter and intra patient variability.
 Improves safety and efficacy of a drug.
 Maximize drug absorption, reduce peak plasma fluctuations, minimize local irritation
of the mucosa by certain irritant drugs and minimize potential side effects without
appreciably lowering drug bioavailability.
1.5. Tablets: The Dominant Oral Dosage Form : 11,12
Pharmaceutical tablets are the dominant dosage forms for drug delivery, occupying two third
of  the  global  market.  Generally,  they are  formulated  by compressing dry powder  blends
consisting  of  a  number  of  components  with  different  functionalities  in  a  die.  With
advancement in technology and a rise in awareness towards modification in standard tablet to
achieve better acceptability as well as bioavailability, newer and more efficient tablet dosage
forms  are  being  developed.  The main  intention  behind  formulation  of  different  types  of
tablets  are  to  create  a  delivery  system  that  is  relatively  simple  and  inexpensive  to
manufacture,  provide  the  dosage  form that  is  convenient  from  patient’s  perspective  and
utilize an approach that is unlikely to add complexity during regulatory approval process.
1.5.1. Different Types of Tablets 
 Tablets ingested orally:  
                1. Compressed tablet
                2. Multiple compressed tablet 
                3. Repeat action tablet 
                       4. Delayed release tablet 
                5. Sugar coated tablet 
                6. Film coated tablet 
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                7. Chewable tablet
 Tablets used in oral cavity: 
                 1. Buccal tablet
                 2. Sublingual tablet
                 3. Troches or lozenges 
                 4. Dental cone 
          
 Tablets administered by other route: 
                      1.  Implantation tablet 
                      2.  Vaginal tablet
 Tablets used to prepare solution: 
1. Effervescent tablet 
2.  Dispensing tablet
3.  Hypodermic tablet 
4. Tablet triturates 
1.5.2. Advantages:
• Dose precision and least content variability.
• Lightest and most compact of all dosage forms.
• They lend  themselves  to  some  special  release  profile  products,  such  as  enteric  or
delayed-release products.
• They are better suited to large-scale production than other unit oral forms.
• Their cost is lowest of all dosage forms.
1.5.3. Disadvantages:
• Some drugs resist compression into dense compacts, owing to their amorphous nature
or flocculent, low-density character.
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• Drug  with  poor  wetting,  slow dissolution  properties,  intermediate  to  large  dosages,
optimum absorption high in the gastrointestinal tract may be difficult or impossible to
formulate and manufacture as a tablet.
• Drugs  with  bitter  taste,  odor  or  sensitive  to  oxygen  or  moisture  may  require
encapsulation or entrapment prior to compression.
1.6 . Compression Machine Tooling 13
The size and shape of a tablet as well as certain identification makings are determined by the
compression machine tooling each tooling set consist of a die and upper and lower punches.
The most common tools employed are referred as BB tooling and are 5.25 inches in length,
and have a nominal barrel  diameter  of 0.75 inches and 1-inch head diameter’s  tooling is
identical  to  BB type except  that  the lower punch is  only 39/16 inches  longed tooling is
popular for large tablets, utilizing a 1- inch barrel diameter, 1.25- inch head diameter, and
5.25- inch length. the dies that are used with the above punches are either a 0.945 – inch
outside   diameter(OD) die capable of making a 7/16 – inch round tablet or 9/16-inch capsule
shaped tablet. 
   Several types of steel are normally used in manufacturing of compression tooling. This
steel differs in toughness, to withstand the cyclic compacting forces (ductility), and in wear
resistance. The selection of the best steel for a specific application must be best on experience
and an accumulated history of the product being tabletted. One should also consider the shape
of the punch tip, whether or not debossing is to be employed on the tooling , the expected
compression  forces  involved,  and  whether  the  materials  to  be  processed  are  abrasive  or
corrosive. 
The size, shape and contour of a tablet are almost unlimited within the given limits of the
specified die size. Tooling can be made with certain other information to aid in producing
visible unique tablet product Company names and symbol, trade names, dosage strength, or
National Drug Code (NDC) numbers can be cut or engraved into a punch face, or the punches
may be scored to produced uniquely embossed or engraved tablets. When the tip of the upper
punch is not round, it must not rotate, or it will strike the edge of the die hole as it descents
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for compression .To prevent this, a slot is curt longitudinally into the barrel of the punch, and
a key is inserted. This key protrudes a short distance so that it engages a similar slot cut into
the upper punch guides on the tablet press. Lower punches do not need keys because their
tips remain within the die bore, which control the axial movement of the punch. Because
keyed punches cannot rotate, wear is distributed unevenly, and punch life is shortened. 
When a press is set up with keyed punches the upper punches are inserted first to determine
the placement of the dies. Once the dies are properly aligned and seated, they are locked in 
place,  and  the lower punches  are  inserted.  The more  curvature  that  is  built  into  a  tablet
contour, the more difficult is to compress, especially if the tablet tends to laminate or cap. The
engraving  or  embossing  on  a  tablet  must  be  designed  to  be  legible,  must  not  add  to
compression problems, and must fit on the tablet surface. Because of its hard steel structure
tablet tooling may appear to be indestructible. During normal use, however, the punches and
die become worn, and the cyclic application of stress can cause the steel to fatigue and break.
The punch tips are especially delicate and susceptible to damage if the tips make contact with
each other, the dies or the press turret upon insertion or removal of the tools from the tablet
machine. To avoid tooling damage, compressive loads or pressure at the pressure rolls must
be  translated  into  a  circulation  of  pressure  at  the  punch  tips.  As  tablet  punch  diameter
decreases, less force is required to produce the same pressure at the punch face, since the face
represents a smaller fraction of a unit area (square inch). The formula for area of a circle is
пr2 where r is the radius of the circle. Given a flat punch face, the area of  22a ¼ - inch
diameter punch would thus be 3.14*(1/8)2 or 3.14*1/64 or approximately 1/20 square-inch. If
a 1-ton load is being applied by the pressure roll, this area is translated as 2000 pounds on
1/20 square inch, or 40,000.
1.7. Coating of tablets: 
   The application of coating is usually based on one or more of the following :
 To mask the taste,odor,or colour of the drug.
 To provide physical and chemical protection to the drug.
 To control the release of the drug. 
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 To  protect  the  drug  from  the  gastric  environment  of  the  stomach  with  an  acid
resistant coating.
 To incorporate another drug or formula adjuvant in the coating to avoid chemical
incompatibility or to provide sequential drug release.
 To provide pharmaceutical elegance by use of special colour.   
1.7.1. Types of coating:
1. Sugar coating
2. Film coating
3. Enteric coating
4. Extended release coating
1.7.2. Layers of  coating in the formulation: 
1. Tablet core
2. Seal coating acts as a inert intermediate layer between the core and outer layer(which
are not compatible with one another).
3. Enteric coating acts as an outer layer which is resistant to gastric juice. 
1.8. Enteric coatings:14
 Enteric coatings are those which remain intact in the stomach, but will dissolve and release
the contents once it reaches the small intestine. Their prime intension is to delay the release of
drugs which are inactivated by the stomach contents or may cause nausea or bleeding by
irritation of gastric mucosa. 
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      The coatings that are used now a day to produce enteric effects  are primarily  mixed  acid
functionality  and acid ester functionality, synthetic, or modified natural polymers. The most
extensively  used  polymers  are  Cellulose  acetate,  poly  vinyl  acetate,  pydroxy  propyl
methyl cellulose, Methacrylic acid copolymers. All these polymers have the common feature
of containing the di carboxylic, pthalic acid in partially Esterified  form
These polymers, being acid esters  are insoluble in gastic media that have the pH of about  4.
And then leave the stomach, and enter into the duodenum (pH 4-6) and further  along the
small intestine , where the pH is increase to a range of (pH 7-8). 
The primary mechanism by which these polymers lose their integrity, is  their by admitting
the releasing drug to the intestinal fluid. in this ionization of the residual carboxyl groups on
the chain and subsequent hydration.
1.8.1. Important reasons for enteric coating are as follows :
    * To protect acid-liable drugs from the gastric fluid
    * To protect gastric distress or nausea due to irritation from drug
    * To deliver drugs intended for local action in the intestines
    * To provide a delayed release component to repeat actions
    * Protect the drugs from harmful effect of the gastric contents; some of the drugs    
are prone to be hydrolyzed in acid media (E.g., omeprazole, pantaprazole)
1.8.2. Ideal enteric coating materials should have the following properties:
    * Resistance to gastric fluids
    * Ready susceptibility to or permeability to intestinal fluids
    * Compatibility with most coating solution components and the drug substrates
    * The film should not change on aging
    * Formation of continuous film
    * Non-toxicity
    * Low cost
    * Ease of application
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1.8.3. Enteric Coating Materials: 
  Enteric coatings polymers are selectively insoluble substances. They  won't dissolve in the
acidic juices  of  the  stomach,  but  they will  when they reach  the higher  pH of  the  small
intestine. Most enteric coatings won't dissolve in solutions with a pH lower than 5.5.  
   Commonly-used enteric coating polymers:
    * Methacrylic acid copolymers
    * Cellulose acetate (and its succinate and phthalate version)
    * Polymethacrylic acid/acrylic acid copolymer
    * Hydroxypropyl methyl cellulose phthalate( HPMCP)
    * Polyvinyl acetate phthalate ( PVAP)
    * Hydroxyethyl ethyl cellulose phthalate
    * Cellulose acetate tetra hydro phthalate
   
The earliest enteric coatings utilized formalized gelatin , this was unreliable because of the
polymerization  of  gelatin  could  not  be  accurately  controlled.  Another  was  shellac,
disadvantage was polymerization with time, resulting in poor dissolution of the coating.
The most extensively used polymers are CAP, PVAP. The most recently used polymers are 
HPMCP, Methacrylic acid copolymers.
 Cellulose Acetate Phthalate (CAP)   :
Effective enteric coating, it only dissolves above pH 6 and may delay drug release 
longer than desired. it is permeable to moisture and simulated gastric fluid in          
comparison with other enteric  polymers and it is susceptible to hydrolytic breakdown
on   storage.
 Poly Vinyl Acetate Phthalate (PVAP) :
Less permeable to moisture and simulated gastric juice, it is more stable to hydrolysis 
on storage. Enteric dosage forms coated with PVAP disintegrates at pH 5
 Hydroxy Propyl Methyl Cellulose Pthalate (HPMCP):
It is available in two grades HP50 and HP55.
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HP55 solutions are more viscous than HP50.
HP50 disintegrates at pH5 and HP55 disintegrates at pH5.5.
It has stability similar to that of PVAP and dissolves in the same pH range. The      
advantage is that it does not require Plasticizer.
 Methacrylic acid copolymers  :15
Two grades are available A B and C which differs in the ratio of free carboxyl to ester 
groups therefore:
Type A - Poly (ethyl acrylate, methyl methacrylate, trimethylammonioethyl 
methacrylate chloride) has a ratio 1: 2: 0.2 and soluble in intestinal fluid from pH 6. 
Type B - Poly (ethyl acrylate, methyl methacrylate, trimethylammonioethyl 
methacrylate chloride) has a ratio of 1:2:0.1 and soluble in intestinal fluid from pH 7.
Type C - Poly (methacrylic acid, ethyl acrylate) 1:1 and soluble in intestinal fluid from
pH 5.5.
       
1.9.  Disease Profile: 16
Acid Related Disease:  Thirty years ago, disorders associated with in appropriate  levels
of  gastric  acid   were  a  major  problem for  which  treatment  option   were  is  limited
approaches  to  the  control  of  gastric  acid.  there  are  number  of  condition  that  may
intravenous acid suppression  including gstric  ulcer Gastro-esophageal reflux disease,
Zollinger Ellison syndrome, Barett esophagus.
1.9.1. Physiology of  Nocturnal secretion of Gastric acid :
       The secretion of acid occurs at a continous  basal level and increase after meals
1. Basal  acid  release  is  stimulated  by  food.  when  meal  containing  protein  is
Consumed,  amino  acid  is  released.  which  stimulates  the  release  of  gastrin  by
g –cells in the Lumen of antrum.
2. And  which  in  turn  stimulates  the  Paracrine  Entero-chromaffin  like  cells  called
histaminocytes located in the oxyntic glands of the stomach to release histamine.
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EC cells is in close proximity to the parietal cells  by which it  binds to specific
receptors.
3. In response to various stimuli ( signals) the parietal cell in the Fundus  of   Stomach
Secrete HCL ( Gastric acid ).
   
    
     Fig  .3  -
Schemmatic
representation of gastric acid secretion from the parietal cell       present in the  lining of
the  stomach
1.9.2. Concept Of Parietal Cell Mass
There are Normally about 109 parietal cell in the stomach (parietal cell mass) under maximal
condition of stimulation. They secrete 20-25meq at low stimulation.the output is 2-3meq/hr.
hence at low volume secretion rates the pH is higher, at higher rates the pH is lower. PCM
varies with gender,age,  body weight pathologies.  Parietal  cells  secrete a fluid of constant
composition  (HCL)  independent  of  rate,  type  or  magnitude  of   stimulus,  the  volume  of
secretion is dependent on the number of parietal cells secreting
Fig .4 - Graph showing the maximum secretion of acid with increasing number of 
parietal cells
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1.9.3. Peptic ulcer : 17
 Peptic ulcer disease refers to pain ful sores  or ulcers in the lining of the stomach or the first
part of the small intestine, the duodenum. Normally a thick layer of  mucus protects  the
stomach lining from the effects of its digestive juices, but many things reduce this protective
layer , allowing for ulcer to occur .
    Classification 
• Type 1: Ulcer along  the body of the stomach , most often along the lesser at incisura 
angularis along the locus minoris resistentiae
• Type2: Ulcer in the body in the combination with duodenal ulcers. with acid            
secretion 
• Type 3: In the pyloric channel  with 3 cm of pylorus.  associated with  acid over          
secretion.
• Type 4: Proximal gastro esophageal ulcer .
• Type 5: can occur through out the stomach. Associated with chronic NSAID (such as 
aspirin). 
  Causes
• The major cause  for peptic ulcer is due to helicobacter pylori, that colonizes the
antral mucosa .
• The immune system  is  unable to clear the infection,  despite  the appearance of
antibodies.  Thus,  the  bacterium  can  cause  a  chronic  active  gastritis  (type  B)
resulting in  a  defect  in  the regulation of  gastrin  production  by the part  of  the
stomach, and gastrin secretion  can either be increased or decreased  resulting in
achlorhydria.
• Gastrin  stimulates the the production of gastric acid by the parietal cells  and the
H pylori colonization  responses to the increase  gastrin,  the increase in acid can
contribute to the erosion  of the mucosa  and there fore ulcer formation occurs.
       Symptoms  
• Abdominal pain
• Bloating
• Hematemesis ( vomiting of blood)
• Melana (foul smelling feces due to oxidized iron from haemoglobin).
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       Diagnosis
• Stomach pain is mainly the first signal of the peptic ulcer.
• Conducting endoscopy test or barium contrast x rays.
• Esophagogastroduodenoscopy (EGD), carried out for the patients with peptic ulcer
suspected .
       Treatment
• Younger  patients  with   ulcer  llike  symptoms  are  often  treated  with  antacids,
H2   antagonists .
• H.pylori infection  are treated with combination of two antibiotics clarithromycin,
amoxicillin, metronidazole and one proton pump inhibitors
• Perforated peptic ulcer requires a surgical repair of the performation .
• Sucralfate  has also been a successful  for the treatment of peptic ulcer.
Table No: 1 – pH conditions of GIT (to match optimized value in biological fluid)
    Region     pH  (Fasted) Resident time
        Mouth      5.8-7.4   <   1 min
        Esophagus      1-5   0.25-3 hrs
        Stomach      1.5-3.5   1-5 hrs
        Small intestine      5.5-7.8   3-4 hrs
        Duodenum      2.4-6.8    > 5 hrs
        Jejnum       6.0-7.0   1-2 hrs
        Ileum       6.5    2-3 hr
        Large intestines       6.2-7   < 8 - 30 hrs
        Colon        8     15-48 hrs
1.9.3. Gastro  Esophageal  Reflux  Disease 18
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Gastro esophageal reflux disease(GERD) is a condition in which the stomach contents    
(food or liquid ) leaks backward from the stomach into the esophagus ( the tube from the
mouth to the stomach ) this action can irritate  the esophagus , causing heart burn .
         Causes
• When you eat, food passes from the throat to the stomach  through the esophagus
once food  is in the stomach , a ring of muscle fibers prevent food from moving.
back ward into the  esophagus . these muscle fibers are called  the lower              
esophageal sphinter (LES).
• If the sphincter  muscle does not close well, food , liquid , form  stomach  can 
leak back into the esophagus . this is called gastro esophagus reflux disease.
       Risk Factors 
• The risk factors for reflux include  hiatal hernia ( a condition in which  a part of the
stomach  moves above the diaphragm, which is the muscle seperates the chest and
abdominal  cavities), pregnancy & Scleroderma
• Obesity ,cigrattes & possibly alcohol increase the chance of the GERD .              
Symptoms 
• Heart burn in the stomach (under the breast bone ).
• Felling that  food may be left trapped behind the breast bone.
       Prevention
• To prevent heart  burn,  avoid following things  such as  smoke, alcohol,  caffeine
spicy or  fatty foods tomatoes , carbonated beverages.
• Over use of NSAIDs should be avoided.
       Diagnosis 
        If symptoms are severe  one or more tests  may help to diagnosis  reflux.
• Continous esophageal reflux monitoring .
• Barium swallow test.
• Esophago gastro duodeno scopy  is often used to identify the cause and  examine 
the esophagus for damage 
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Treatment 
• Ant acid can be used  but the common side effects of ant acid includes diarrhea or 
constipation.
• Proton pump inhibitors :are the most  potent acid inhibitors , omeprazole,     
pantoprazole rabeprazole ,esomeprazole.
• H2 antagonist: famotidine,cimetidine, ranitidine.
• Anti-h.pylori drugs :clarithromycin,amoxicillin.
1.9.4. Zollinger –Ellison Syndrome 
Zollinger  Ellison syndrome is a rare disorder, characterized byone or more tumours in the
pancreas, duodenumor both. The tumour cause the stomach  make to much acid, leading
to  peptic ulcer in the duodenum. The tumours are some times cancerous & spread to the
other areas of the body .
Causes
Zollinger Ellison syndrome is caused by tumours called gastrinomas, which release the
hormone gasrin. Normally , cells in the stomach  produce and control gastrin  so only the
right amount is released . gasrin travels through the blood streams to signal other cells in
the  stomach   to  release  gastric  acid  in  the  stomach  and  duodenum.The  excess  acid
eventually  causes  sores  called  peptic  ulcers.  To  form in  the  linig  of  the  duodenum.
Majority of gastrinomas . which  appper sporadically.  about 25% of gastrinomas  cases
are caused by by an inherited  genetic  disorder.   Multiple  endocrine   neoplasia  type
1(MEN 1).
       Symptoms
• Burning  abdominal pain 
• Nausea and vomiting 
• Weight loss
• Diarrhea
       Diagnosis
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• Measuring  stomach acid and the amount of gastrin circulating in the blood.
• Conduting imaging tests to 100k for gastrinomas. 
• Somatostatin  receptor  scintigraphy  is  used  to  find  gastrinomas  in  the
duodenum  pancreas  &other  parts  of  the  body  SRS  is  used  as  a  radio  active
compound called a radio tracer that when injected into the blood stream, selectively
tumour cells. 
• The labeled cells light up  when scannrd with a device called gamma camer
• Angiography  some timeused to find tumours in the pancreas.
• Computerized tomography scan  takes  hundred of cross sectional x- ray  images  in
a few seconds a computer assembles  the images to produce  three dimensional
views of  internal organs.
       Treatment                     
Proton pump inhibitors effectively  reduces gastric acid secretion in the stomach  and 
includes,
• Pantoprazole(protonix)
• Omeprazole(prilosec)
• Eesomeprazole(nexium)
 Reducing stomach acid  allows peptic ulcer to heal relives ZES symtoms,surgical     
removal of gastrinomas is the only cure for ZES. some gastrinomas behave like    
cancer and spread to the other Parts of the body , especially the liver and bones .
 Classification of Acid suppressive Agents 19
• H-2 Receptor antagonist–  Cimetidine, Ranitidine, Famotidine.
• Protonpump inhibitors– Omeprazole,Pantoprazole, Rabeprazole, Lansoprazole.
• Anticholinergics  –  Pirenzepine,  Oxyphenonium, Prophantheline.
• Prostaglandin analogue– Misoprostol.
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               Table No: 2 - Mechanism of Action of  Acid suppressive Agents 19
1.10. D
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The  Most  potent  inhibitor  of  gastric  acid   secretion  is  proton  pump  inhibitors,  has
revolutionalized the treatment  of  Acid related  disorders,  such  as  GERD,  ZES,  Idiopathic
hyper secretion, stress related or drug induced erosive gastritis. 
Omeprazole was the first drug in the class introduced in 1989, since then four other PPI´s has
been  introduced they are Lansoprazole (1995),Rabeprazole(1999),Pantoprazole (2000), And
Esomeprazole(2001).   
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         Acid suppressive agents
           Mechanism of action
Prostaglandin analogue
It inhibits the gastric secretion by opposing 
Camp generation in parietal cells and gastrin 
release from antral cells.
H-2 receptor antagonist It performs by blocking the action of histamine 
on parietal cell in the stomach  by this decreasing
the production of gastric acid from the cell.
Proton pump inhibitor
 
PPIS acts by irreversibly blocking the enzyme 
system of the parietal cell  by this it terminate the
final stage in the gastric secretion.
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1.10.1.  Mechanism of action of Proton pump inhibitors
The key action of the  PPI´s is to decrease gasric acid and secretory volume. It acts by
blocking  the  enzyme  system  responsible  for  active  transport  of  acid  into  the
gastrointestinal  lumen,  namely  the  hydrogen  /potassium-  adenosine  triphosphate
known as (Acid pump or  Proton pump ).an enzyme present in the gastric parietal
cells this effect on the final step of the gastric acid formation there by reducing gastric
acid  output  both  during  basal  condition  and  simulated  acid  secretion,
irrespective of stimulus.
                                Fig .5 - Mechanism of Action of PPI´s 
1.10.2. Biopharmaceutical classification system  : 20
According to the Biopharmaceutical classification system  (BCS), drug substances are 
classified  as follows:
• Class I -            High permeability, High solubility.
• Class II -            High permeability, Low solubility.
• Class III    -           Low permeability, High solubility.
• Class IV    -           Low permeability, Low solubility.
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 Class I drugs are likely to exhibit few bio availability problems.
 Class II drugs are prone to dissolution rate- limited  absorption.
 Class III drugs are likely to exhibit permeation rate-limited absorption.
 Class IV drugs may be present serious obstacles to oral bio availability, and some may be
best formulated in a solubilized form such as a liquid filled or semi solid-filled capsule.
 Pantoprazole belongs to class III drugs of the BCS, characterized by high solubility and 
low permeability.
 Table No: 3 –Pharmacokinetics of Delayed Release Proton-Pump Inhibitors
S.No Parameters     Pantoprazole Omeprazole Esomeprazole
1 Absolute
Bioavailabilty (%)
               77 40 64-90
2 Time to peak
plasma  Level ( h )
2-4 0.5-3.5 1.5
3 Plasma 
half- life (h)
1.0 0.5-1.0 0-1.5
4 Plasma protein
binding (%)
97 95 97
5 Hepatic
metabolism
Yes Yes Yes
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2. AIM & OBJECTIVES
The aim of  the  present  study was to  develop a  pharmaceutically equivalent,  stable,  cost
effective and quality improved formulation of Pantoprazole Sodium enteric coated tablets.   
To achieve these goal various prototype formulation trails were taken and evaluated with
various quality control such as dissolution, assay. the formula was finalized by comparing the
in vitro dissolution profile with that of the marketed  tablet.
Objectives:
• To formulate and evaluate delayed release tablets of Pantoprazole sodium.
• To determine the best fit dissolution profile for the formulated dosage form.
• To study the release profile of the dosage form and to compare their drug release
profile  with the innovator product.
• To study the stability of formulated  dosage form and compare with the specifications.
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3. PLAN OF WORK
1. Literature survey.
2. Preformulation studies
• Evaluation of API.
• Drug-Excipients Compatibility Studies.
3. Selection of excipients based on Drug excipients compatibility data.
4. Preparation of granules of Pantoprazole sodium by Wet granulation method.
5. Evaluation of pre compression studies for the final blend of all formulations.
• Bulkdensity, Tap density.
• Compressibility index,  Hausner´s ratio.
• Angle of Repose,  Moisture Content.
6. To perform Coating of Compressed tablet.
• Seal coating. 
• Enteric coating.
7. Evaluation of post-compression parameters
• Hardness, Thickness,Weight variation .
• Dissolution study, Disintegration test.
• Drug content (Assay).
8. Selection of bioequivalent  formulation by comparing  invitro dissolution profile of
formulated batches with that of innovator product – Determination of  f1 ,f2 factor.
9. To perform Stability studies for final optimized formulation.
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4. LITERATURE REVIEW
 Kishore Babu , N. Bhanu Teja, B. Ramakrishna et al.,21 Designed  and developed
gastro resistant drug delivery system for pantoprazole. Pantoprazole is an acid labile
drug, whichcan be degraded in the stomach. Therefore, the drug should be targeted to
intestine; tobypass the stomach the gastro resistant double walled microspheric drug
delivery systemwas adopted. The formulations were developed consisting of double
wall.  The primary wallcomposed of muco adhesive polymer HPMC and a release
controlling polymer sod.Alginate. The second wall coating the primary microspheres
was composed of eudragit RS100. Eudragit RS 100 provides sustained drug release
upto 14hrs with the influence of pH 7.4buffer. The effect of polymer concentration on
the  particle  size,  shape  drug  entrapmentefficiency,  muco  adhesive  property,  and
release study of core microspheres were evaluated.
 Santosh Kumar Jindal et al.,22 Formulated and evaluated oral drug delivery device
for insulin and to protect the sensitive drug from digestive enzymes and proteolytic
degradation in stomach and upper part of gastro intestinal tract (GIT). So, for this
purpose  insulin  enteric  microspheres  (EMS) were  prepared  using Hydroxy propyl
methyl cellulose acetate succinate as enteric polymer,. In-vitro drug release studies
determined that almost no drug was released in HCl (pH 1.2) for 2 hours and then
maximum amount of drug was released within 70 minutes in Phosphate buffer (pH
7.4). In-vivo studies on male wistar rats confirmed a remarkable decrease in blood
glucose level  after 2 hours of administration of insulin EMS.
 Rajesh z. mujoriya et al.,23  Formulated and evaluated  pantoprazole sodium enteric
coated  pellets.Before  going  to  develop  the  formulation  a  detail  product  literature
review was carried out to know about the MUPS and type of dosage form available in
market. The present study was focused to formulate delayed release capsule by MUPS
Technique.Average pellets  size was determined by sieve analysis  and found to  be
(ASTM  sieve  no.  12-16).  Sieve  analysis  was  the  essential  step  before  coating.
Because  uniform  sized  pellets  undergo  effective  coating.  The  result  indicates  a
effective enteric coating and delay the drug release, with 32% acryl ezee solution, is
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possible. The formulation developed can further be worked on. For identifying a best
formulation for delayed release pellets of  pantoprazole sodium.
 Juliana Siqueira Chaves et al.,24 Formulate and evaluated the spray-dried extract of
feverfew and further designing and standardizing enteric coated tablets. In this work,
the spray-dried extract of feverfew was evaluated for its parthenolide, santin and total
flavonoid  content,  parthenolide  solubility,  particle  size,  tap  density,
hygroscopicity,  angle  of  repose  and  moisture  content.  Tablets  containing  the
spray-dried  extract  were  tested  for  their  average  weight,  friability,  hardness,  and
disintegration time. The total flavonoid and parthenolide contents in the spray-dried
extract were 1.31 % and 0.76% w/w, respectively. The spray-dried extract presented
consistent  pharmacotechnical  properties  and  allowed  its  tableting  by  direct
compression. Tablet properties were in accordance with the proposed specifications.
The procedures described herein can be used to prepare and evaluate pre-formulations
of  feverfew  with  adequate  properties  for  the  development  of  a  high-quality
phytomedicine.
 Ajit Patil ,  John Disouza et al.,25  Formulated and evaluated enteric coated tablets for
azithromycin  dihydrate  to  reduce  th  Gastrointestinal  tract  side  effects.Three
formulations of Core tablets were prepared and one whoshows rapid disintegration
(below three minutes) was selected for enteric coating . Enteric coat was employed by
usingdifferent  polymers  such  as  HPMC-55,  Eudragit,  Ethyl  cellulose  in  different
ratios  Combination  of  HPMC-55  and  ethylcellulose  (10:1.5)  exibited  better
dissolution ,disintegration, hardness and friability properties .This study concluded
thatenteric  coated  tablets  of  azithromycin  dihydrate  can  be  prepared  by  using
combination of polymers studied and we can reduce the GI tract side effects.
 Sanjay R.et al.,26  Developed  and evaluated the enteric coated tablets of Rabeprazole
sodium  by  using  Methacrylic  acidcopolymer  (Colorcoat  EC4S)  and  to  optimize
coating process parameters which implicate more significant effects on tablet coating
process.  The  different  batches  of  uncoated  tablets  were  prepared  by  both
wet  granulation  and  direct  compression  method.  Batch  B6  of  uncoated  tablets
preparedby direct compression method shown good results of evaluation parameters
compared to other  batches.  Results  of the preliminary trials  indicated that  process
parameters individually affected the quality of coated tablets. At this point of time it
was seen that spray rate, inlet air temperature and hence to study the combined effect
of  this  factors  on  the  coating  process,  33  full  factorial  design  was  applied.
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Comparative study of   dissolution profile of final batch with market preparations was
conducted and it   was  concluded that final formulation F shown good similarity with
market products.  The results  of the accelerated stability of final  formulation F for
3months revealed that storage conditions were not found any significant changes in
final  formulation F.  The photoinstability of  the rabeprazolesodium showed by the
photostabilty studies      indicated that special care to avoid exposure of the drug to the
light effects must be taken during themanufacture and storage of the pharmaceutical
preparations.
 Banerjee  T,  Muruganantham  et  al., 27 Designed  and  developed  novel
sustained-release  (SR)  Muco  adhesive  tablet  formulations  of  naproxen  sodium  a
non-steroidal  anti  inflammatory  drug.  Pantoprazole  Sodium  is  added  to  the
naproxen to overcome the side effect such as ulcer and bleeding. Sustained release
tablets  Naproxen formulated by using polymers such as sodium alginate, gelatin and
carbopol 934P. A combination of hydrophilic polymers was used in the ratio of 1:1:1
to1:1:5  along  withusual  tablet  additives  like  lactose  and  MCC.  The  compressed
Mucoadhesive tablets were evaluated for various parameters like hardness, friability,
weight variation, drug content uniformity which shows the drug content was uniform
in all the formulations of thetablets prepared. IR studies indicated that  the drug is
compatible withthe polymers and stability studies also performed were no appreciable
difference was observed.  The in-vitro release of  Naproxen and Pantoprazole were
studied by using the buffer solutionof pH 1.2. The in-vitro release of drug showed that
tablets (batch F9)of combined S: G: C is 1:1:5 containing tablets (96%) at the end
of10thhour and was found to release the drug.
 Damodharan ,  Manimaran V et  al.,28 Developed  and evaluated small  intestine
targeting tablets of doxycycline hydrochloride by wet granulation method and enteric
coating of tablets (conventional  standard coating technique).This drug is universal
antibiotic and can be targeted to the specific site of absorption by enteric coating
using  pH  dependant  polymers.Polymers  like  Eudragit  and  HPMC  Phthalate  are
selected  where  dissolution  is  above pH 6 and pH 6.4 respectively.Preformulation
studies  like  angle  of  repose,  bulk  density,  tapped  density,  porosity,  Carr's  index,
Hausner's ratio wereperformed. Six batches (F1 to F6) were formulated and evaluated
for  hardness,  friability,  weight  variation,  drugcontent,  disintegration  and  in‐vitro
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dissolution. Among the six batches, batch F4 was showing 94% drug release and was
considered to be best formulation.
 Anroop B Nair, Rachna Kumria1et al.,29   Formulated and evaluated enteric coated
tablets  for  Esomeprazole  magnesium  trihydrate.  Different  core  tablets  were
preparedand formulation (F-1) was selected for further    enteric coating, based on the
disintegrationtime.  Seal  coating  was  applied  to  achieve  3%  weight  gain  using
opadry®.  Entericcoating  was  carried  out  using  different    polymers  like
Eudragit  L-30  D-55,  hydroxy  propylmethylcellulose  phthalate,  cellulose  acetate
phthalate and Acryl-EZE® to achieve 5% weight gain. Disintegration studies showed
that the formulations failed in 0.1 NHCl media. Hence the quantity of enteric coating
was increased to 8% w/w.  In vitroanalysis of the developed tablets was carried out.
Results  from disintegration  time and  dissolution  rate  studies  indicate  that  all  the
esomeprazole enteric  tablets prepared possess  good integrity,  desirable for  enteric
coated tablets. Among the polymers studied,the methacrylic polymers exhibited better
dissolution  rate  than  the  cellulose   polymers.Stability  studies  indicate  that  the
prepared formulations were stable for a period ofthree months. This study concluded
that enteric coated tablets of esomeprazole canbe prepared using any of the enteric
coating polymer studied using a minimal weight gain of 8%.
 Hemanta Kumar Sharma,  Siba Prasad   et  al.,30  Designed and  formulated  the
Pantoprazole  loaded  microbeads  by  ionotropic  gelation  technique  using  sodium
alginate  and  natural  Mucoadhesive  substance  from  the  fruit  of  Dillenia  indica
followed  by  a  coating  with  Eudragit  L100-55.  The  microspheres  have  been
characterized  in  terms  of  theirmorphology,  particle  size,  encapsulation  efficiency,
swelling ratio, mucoadhesivity and ability of stabilizingPantoprazole in acidic media.
Different formulation variables like polymer-polymer ratio, drug-polymer ratio and
coating concentration were considered. Almost spherical microbeads were obtained
with  sufficient  swelling,Mucoadhesive  property  and  acid  resistance.  Dissolution
study was followed at phosphate buffer (pH 7.4) for 8 hr.
 Rabia Bushra1,Muhammad Harris Shoaib et al.,31   Developed and investigated
the  enteric  coated  ibuprofen  tablets  in  order  to  avoid  gastric  mucosal  irritation,
diffusion of drug across mucosal lining and to let active ingredient be absorbed easily
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in  small  intestine.  The formulation was  developed  and  manufactured  through the
direct  compression process,  the simplest,  easiest  and most economical  method of
manufacturing. Enteric coating was done using an Opadry white subcoating and an
aqueous coating dispersion of Acryl-Eze. Enteric coated formulation was subjected to
disintegration and dissolution tests by placing in 0.1 M hydrochloric acid for 2 h and
then 1 h in phosphate buffer with a pH of 6.8. About 0.04% of drug was released in
the acidic phase and 99.05% in the basic medium. These results reflect that ibuprofen
can be successfully enteric coated in order to prevent its release in the stomach and
facilitate rapid release of the drug in the duodenum, due to the presence of super
disintegrant. Formulating this enteric coated tablets could increase patient compliance
by decreasing adverse drug reactions (ADRS) associated with Ibuprofen therapy.
 Chanchal Kumar Mishra, Anil Goyal,et al.,32 Investigated the Pantoprazole and its
enteric coating polymer concentration for stable coating in acid media which is an
orally  administered  benzimidazole  anti-ulcer  drugs.  To  achieve  this  goal,  various
prototype  trials  were  taken  and  evaluated  with  respect  to  the  various  quality
parameters  such  as  disintegration,  tablet  weight,  thickness;  diameter,  gastric
resistance  test,  drug  uniformity  and  dissolution  also  determine  optimum polymer
concentration  for  enteric  coating.  Pantoprazole  enteric  coated  tablets  prepared  by
direct compression. Because of its unstability in acidic environment decided to give it
alkaline  environment  with  the  help  of  alkaliser  and  also  protective  seal  coating
between core tablet and acid resistant enteric coat. The primary aim of using delayed
release is to protect the drug from an unfavourable environment in the gastrointestinal
tract,  to  protect  the  gastrointestinal  tract  from  high,  local  concentrations  of  an
irritating  drug  compound,  or  to  target  a  specific  region  of  absorption  or  action.
Delayed  release  products  are  typically  enteric  coated  or  colon  targeted  system.
Formulation can be evaluated by Acid resistant  test and  In vitro  drug release test.
Delayed  release  dosage form has  an enteric  polymeric  coating with characteristic
pH-dependant solubility (or stability) to prevent release of the active ingredient in the
stomach at  low acidic pH (i.e.  1-3).  Once the delayed release product  leaves  the
stomach,  the  enteric  coating  dissolves  subsequent  in-vivo  drugs  release  and  then
generally  follow  the  same  course  as  for  an  immediate  release  product.  Applied
different parameters of enteric coated tablets evaluation and IR spectral analysis of
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Pantoprazole  that  justified  the  enteric  coating  polymer  concentration  for  stable
coating in acid media in stomach.
 Rupesh  S.  Kamble,  Archana et  al.,33 formulated   and  evaluated Enteric  Coated
Dosage  Form  using  Ketorolac  Tromethamine.  Reduction  of  side  effects  while
prolonging  its  action  by  using  controlledrelease  of  oral  dosage  forms  is  highly
desirable. In the present study direct compression method is used for the preparation
of  fabricated  batches  and  EudragitL100  is  used  as  coating  polymer  for  enteric
coating.  In  vitro  release  profiles  of  batches  F1-F4  shows  that  KetorolacTro
methamine drug:polymer ratio with Guar gum, Xanthan Gum, Ethyl cellulose and
Sodium alginate give 79.32%, 91.52%, 88.35%and 92.19% drug release respectively
in  12  hours.  In  vitro  release  profile  of  batches  F5-F8 shows f  85.21%,  95.52%,
93.50%, 97.24% respectively in 12 hours. In vitro release profile ofbatches F9-F12
shows that  Ketorolac  Tromethamine  in  ratio  1:3  with  Guar  gum,  Xanthan  Gum,
Ethylcellulose  and  Sodium  alginate  gives  release  of  89.50%,  98.25%,  95.22%,
100.27% respectively in  12hours.  2 andthen showed higher  increase in phosphate
buffer of pH 6.0 up to 12 hours. All these batches follow near zero order kinetic. This
indicates  that  the  Guar  Gum,  Xanthan  Gum  and  Ethyl  cellulose  and  Sodium
alginate at minimum concentration is not only able to sustain but also control  the
drug release.
 Rajeshwar Arya, Vijay juyal et al.,34  Investigated and  developed a  gastro resistant
drug delivery system for pantoprazole. Pantoprazole is an acid labile drug, which can
be degraded in the stomach. Therefore, the drug should be targeted to intestine; to
bypass  the  stomach  the  gastroresistant  double  walled  microspheric  drug  delivery
system was adopted.  The formulations  were developed consisting of double wall.
Theprimary  wall  composed  of  mucoadhesive  polymer  sod.  CMC  and  a  release
controlling polymer sod. alginate. The second wall coating the primary microspheres
was composed of eudragit S‐100.The effect of polymer concentration on the particle
size, shape drug entrapment efficiency,mucoadhesive property, release study of core
microspheres were evaluated.
 Rahman A et al.,35 Developed and evaluated multiparticulate  formulation of sodium
para  amino  salicylate  for  oral  administration  was  developed  by  extrusion
spheronization  technique.  micro  crystalline  cellulose  was  used  as  filler  in
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concentration of 14.4%W/W. pellets were coted with eudrajit L30 D55 using fluid
bed processor. Different weight gains of acrylic polymer were applied onto the pellets
and evaluated for invitro dissolution behavior in 0.1 N HCL for 2  hours and then
media was changed to phosphate buffer pH 6.8. a 60%w/w coating level of Eudrajit
L30 D55 has produced the most acceptable results against the gastric attack. 3%  seal
coat  of HPMC E5 was applied in order to protect the drug from migration into the
eudrajit coat and flim coat was applied in order to prevent aggregation of pellets  in
the  dissolution  media.morphological  characteristic  of  developed  pellets  were  also
investigated by scanning electron microscopy and found to be smooth and spherical.
Developed  system  was  found  to  be  suitable  for  the  delivery  of  sod  PAS   into
intestinal region.
 Subramaniam  Kannan,  Rangasamy  Manivannan  et  al.,36 Formulated  and
evaluated the enteric coated aspirin tablets.The delayed release tablet is intended to
release the drug after some delay or after tablet pass GI tract. The enteric coating is
common example of this tablet. All enteric coated tablets are delayed release tablet
but all delayed release tablet are not enteric coated tablets.1 Aspirin delayed release
tablet is used to increase bioavailability and to reduce risk of hospitalization for heart
failure,  coronary  thrombosis  deliver  drug  at  a  near  constant  rate  for  24hr.  2,10
Keeping these factors in view it is aimed to formulate, evaluate and stabilize Aspirin
(75mg)  DR tablet  to  provide  a  controlled  and  predictable  release  of  Aspirin  and
which is used in the treatment of Coronary Thrombosis (heart disease)13, for Once in
Day administration. The half life of Antiplatelet agent is 6 Hours which makes it
suitable candidate for delayed release formulation. The present work aims to avoid
degradation of drug in acidic environment of stomach. So due to enteric coating drug
releases in to the small intestine so that drug gets larger surface area for absorption.
Micro crystalline cellulose,  maize starch,  cross carmilose Sodium is a disintegrent
used  to  prepare  a  blend  for  direct  compaction  method.  Aspirin  anti-platelet
compounds  which  suppress  or  inhibit  the  cyclooxygenase  enzyme  which  is
responsible  for  the  formation  of  thromboxane  A2,  thus  block  the  formation  of
thromboxane A2. Thromboxane A2 is a  activator of platelet  aggregation.3,12 Hence
our present study was performed on these formulations as aspirin delayed release
tablet.
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 US  Patent2003/5,997,903: 37  It  discloses  an  orally  administable  medicament  in
tablet/pellet form  that is resistant to gastric juice which consist of  a core of active
compound admixed with binder , a filler , basic physiologically tolerated  in organic
compound , an inert  water soluble intermediate layer surrounding the core , an outer
layer  which is resistant to gastric juice.
 Prathima  srinivas  et  al.,38 Formulated  and  evaluated  duloxetine  hydrochloride
delayed release enteric  coated pellets  in  capsules.  Since Duloxetine hydrochloride
degrades in the acidic environment, it is important to by pass the acidic pH of the
stomach. Protection of drug from acidic environment is done by coating the drug with
enteric polymers by using suspension layering technique in Fluidized bedprocessor
(FBP)  with  different  enteric  polymers  like  PVAP  (Poly  vinyl  Acetate
phthalate),Kollicoat MAE 30 DP, Eudragit L30 D55 (Methacrylic acid copolymer)
and HPMCP (Hydroxy propyl methyl cellulose phthalate).  Eudragit  L30 D55 is a
good enteric material. Based onthe vendor data and details, drug release shows after
pH6.5  buffer,  where  as  marketed  preparation  release  starts  at  pH  5.5  buffer.  So
Eudragit was not taken for further trails. The prepared pellets were studied for their
Invitro release studies and were analyzed by using HPLC technique. The released
kinetics was analyzed using the zero-order model, first-order model and Higuchi’s
square root equation. FT-IR (Infrared spectroscopy) and DSC(Differential Scanning
Calorimetry)  studies  were  performed  to  know the  compatibility  of  the  drug with
various excipients and SEM (Scanning Electron Microscopy) analysis performed to
know  the  particle  size  and  morphology  of  the  pellet.  The  results  depicted  that
HPMCP gave a good dissolution profile and process suitability compared to Eudragit
L30  D55,Kollicoat  MAE  30DP  and  PVAP  and  hence  optimized  based  on  the
similarity factor (f2value).
 Raju, Padmavathy et al.,39  Investigated and developed enteric coated  tablets of
prednisolone and to reduce the side effects of anti inflammatory drugs in G.I.T. by
developing conventional tablets of prednisolone by wet granulation technique and the
prepared prednisolone based tablets were coated with different ratios of pectin and
ethyl cellulose as enteric coating material by spraying organic system. The enteric
coated tablets of prednisolone were subjected to an in vitro drug release study in the
presence and absence of pectinolytic enzyme using simulated colonic fluid of pH 6.0
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as the dissolution medium.. Colon drug delivery is advantageous in the treatment of
colonic  disease,  where  oral  deliveries  of  drugs  are  unstable  or  susceptible  to
enzymatic degradation in upper GI tract.  In  this study,  coated tablets which were
resistant to gastric and small intestinal pH conditions but dissolving in colonic pH
conditions were fabricated., D batch results matched with our theoretical profile.
 Putta  rajesh kumar et  al., 40   Designed  and  evaluated  the  directly compressible
esomeprazole magnesium trihydrate enteric coated tablets were prepared to deliver
drug  in  upper  git,  different  tablets  were  prepared  with  super  disintegrants  like
Ac-Di-Sol,  crospovidone  ,sodium  starch  glycolate  and  diluents  like  pharmatose
DCL1, mannogem EZ, tablets were enteric coated using Acryl-EZE. The tablets were
evaluated for hardness,disintegration time and    invitro drug release. The powder bed
showed good rheological properties and enteric coated tablets showed acid uptake
value <5 indicates significant protection of of acid labile drug. The compressional
parameters were with in the limits,the drug content in all  formulation was found to
be uniform and consistent.invitro dissolution studies indicated there is no drug loss
during gastric phase.the tablets wth pharmatose  which could be due to swelling of
the super disintegrant. Stability      studies indicated  that the prepared formulation
were   stable  for  a  perid  of  four  months  of  all  formulations  showed  comparable
dissolution profiles with similarity factor more than fifty p< 0.05. orom the above
findings it can conclude that an      esomeprazole magnesium trihydrate enteric coated
could developed to deliver the drug into peoximal small intestine.
 De macknkeey et al.,41   Studied   the Plasma and urine concentrations of 5-ASA and
its N-acetyl metabolite 5-AcASA were measured over 48 h in 12 young healthy male
subjects,  who  received  three  doses  of  threet  imes  enteric  coated  500  mg
5-ASAtablets at 7 h interval, on two occasions 14 days a part.on one occasion the
doses were given after standard meals; on the other occasion, they were given 1 h
before  meals.  Administration  of  the  tablets  after  meals  delayed  systemic  drug
absorption but did not affect the extent of absorption. There was a sharp rise in the
plasma  concentrations of 5-ASA and 5-AcASA in the early morning of the 1st dose   
Independent of when the tablets were taken with respect to the meals.. Thus, diurnal
effects may be more important than prandial effects in the evaluation of the kinetics
of 5-ASA and its metabolites after per oral administration of enteric coated tablets.
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 Sumit  Chakraborty,  Sibaji  Sarkar  et al.,42 Formulated  and  evaluated  the
pantoprazole  sodium  enteric  coated  tablets  .This  compound  inhibits  gastric  acid
formation and there by it is very efficient for the treatment of gastric and duodenum
ulcers.  In  aqueous media more  acidic  than pH 4 it  suffers  a practically complete
decomposition  within  a  period  shorter  than  10  minutes.  Even  in  solid  state  it  is
sensitive to  heat,  ,  light  and especially to substances containing an acidic group.
Pantoprazole which is an acid labile drug  it degrade on the stomach pH , can be
coatedwith a substance that will only dissolve in the small intestine. For such types of
drugs, enteric coating added to the formulation tends to avoid the stomach's acidic
exposure, delivering them instead to a basic pH environment (intestines pH 5.5 and
above) where they do not degrade, and give their desired action. 
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5. MATERIALS AND INSTRUMENTS
                  
5.1.  List of Materials used:
                                                         Table No - 4
S.No Name of Ingredients Category Manufacturer/Suppliers
Tablet core   
1 Pantoprazole sodium Drug  Vasudha pharma ltd, india
2 Mannitol Filler Roquette-france 
3 Cros povidone Dis integrant Blagden Specialty Chemicals 
4 Sodium carbonate Alkalizing agent S D fine  chemical
5 Povidone Binder Blagden Speciality Chemicals 
6 Magnesium stearate Lubricant Kant Healthcare
7 MCC (avicel pH112 ) Filler Fmc biopolymer –USA 
8 Aerosoil Glident Wacker Chemical Corp
9 Purified water Vechicle Fourrts india ,chennai
Seal coating 
10 HPMC 15 cps Film former Dow chemicals 
11 Propylene glycol Plasticizer Fisher Scientific UK Ltd
12 Titanium dioxide Opaquant   Kronos ltd
13 Purified water Vechicle Fourrts india ,Chennai
Enteric coating
14 Eudrajit-L30 D-55 Enteric coating  flim former Degussa international 
15 Diethyl phthalate Plasticizer Vopak USA Inc
16 Titanium dioxide Opaquant Kronos   ltd 
17 Purified talc Anti tacking agent Vijaya minerals
18 Triethyl citrate Plasticizer Morflex 
19 Ferric oxide Colouring agent Colorcon asia limited
20 Purified water Vechicle Fourrts india, Chennai
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5.2.  List of Equipments/Instruments:            
                                                                                           
                                                            Table No- 5
S.No. Name of the Equipment Manufacturer
1. 8 station compression machine Accura, Ahmedabad
2. Electromagnetic sieve shaker EMS 8.
3. Friability test apparatus (ET-2) Electrolab, India.
4. Bulk density apparatus Campbell electronics, Thermonick.
5. Fluid bed processor Paam Glatt.
6. Hardness tester Monsanto.
7. Disintegration test apparatus (ED-2L) Electrolab, India.
8. Dissolution apparatus (Disso 2000) Lab India.
9. UV-Visible spectrophotometer (UV-1601) Schimadzu-corporation, Japan.
10. pH meter (Digital 7007) Lab india.
11. IR Moisture balance OHAVS moisture balance
12. Electronic weighing balance (AR 2140) Adventurer Mettler Toleda.
13. Digital Vernier Caliper Mitutoyo Corp., Japan.
14. FT-IR spectrophotometer (FTIR 8300) Perkin elmer, 
15. Hot air oven Pathak electrical works.
16. Stability chamber Thermolab.
17. HPLC with PDA/Binary system Schimadzu Corp., Japan.
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6. DRUG AND EXCIPIENTS PROFILE
 
6.1.  Drug profile: 43,44,45,46,47
      Drug name                :   Pantoprazole sodium sesquihydrate
Molecular formula    :   C16 H14 F2 N3 Na O4 S X  1.5 H2O
Molecular weight      :    432.4 g/ml
Structural formula :  
Chemical Name : 
 Sodium 5-(difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl]-1H-
Benimidazole Sesquihydrate.
Description        :  A white to off-white crystalline powder, and is racemic.
Dosage :
• Gastric ulcer: 40 mg once daily for 8 weeks.
• Gastro esophageal reflux disease:10, 20, or  40mg  once daily for 8 weeks.
• Zolinger –Ellison Syndrome: 40 mg twice daily, may require dosage upto 
240 mg  daily for more than 2 years.
Half Life           :    1 hour, because of  binding extend to  24 hours approximately. 
Solubility          :  Freely soluble in water; slightly soluble in chloroform  and practically 
                              in soluble in n-hexane.       
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      Wave length          :      288 nm (pH 6.8 phosphate buffer );  305 nm ( HCL )
       Standard               : Assay :  Pantoprazole sodium delayed release tablets contain an  
                                         amount of  pantoprazole  equivalent to not less than 90% and not   
                                         more than 110 % of  the  labelled amount of pantoprazole.
                                   Dissolution : Not less than 75% of labeled amount of                  
                                   pantoprazole in 45mins.
   BCS classification      :  Class III (Solubility – High; Permeability – Low)
  Therapeutic Category :  Proton pump inhibitor.
  Route Of Administration :  Oral, I.V
     Mechanism of Action:  
Pantoprazole  is  a  substituted  benzimidazole  compound which  inhibits  the  secretion of
gastric acid in the stomach by specific action on the proton pump in the parietal cells.
Pantoprazole is  converted to its  active form in the acidic channel of the parietal  cells
where it binds covalently with Cysteine 813 in the luminal loop between transmembrane
domains 5 and 6 on the alpha sub unit  of the adenosine triphosphatase enzyme at the
parietal  cell  this  effect  leads  to  inhibition  of  both  basal  and  stimulated  gastric  acid
secretion,irrespective of  the   stimulus.  the  because  of  drug  irreversible binding to  the
H+K+ATPase results in a duration of Anti Secretory effect that persists longer than 24
hours for all the doses tested.
     Advantage of  Pantoprazole over other Proton pump inhibitors:
• Good solubility and very high solution stability allowed it to become the first        
marketed proton pump inhibitior for intravenous use in critical care patients.
• Drug –Drug  interaction of Pantoprazole is very less compare to other proton pump 
inhibitors 
  
                       
      PHARMACOKINETICS:
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      Absorption & Bioavailability : 
• Pantoprazole sodium is a acid labile drug  so it is prepared as  enteric coated  tablet,
and it is well absorbed in the gastrointestinal tract after oral administration.
• The absolute bioavailability of  of Pantoprazole sodium is 77%. The absorption of
pantoprazole is rapid ,with a Cmax of 2.5 µg/ml that occurs  approximately 2.5 hours
(tmax). After administration of a single or multiple oral 40mg doses of   Pantoprazole.
• The total area under curve(AUC) is 4.8 µg/ml. the Pantoprazole is well absorbed; it
undergoes little first pass metabolism. 
  Distribution: 
• Apparent volume of distribution of Pantoprazole is approximately 11.0-23.6 Litres,
distributing mainly in extracellular fluid.
• The serum protein binding of Pantoprazole is about 98%, primarily to Albumin.
  Metabolism: 
     Pantoprazole is  extensively metabolished in the liver  through the Cytochrome p450
system. Pantoprazole is  independent of the route of administration (i.v or oral).  the main
metabolic is   demethylation, by Cytochrome p2c19, with subsequent sulfation There is no
evidence  that  any  of  the  pantoprazole  metabolites  have  significant  of  pharmacological
activity. Cytochrome 2c19 displays a known genetic polymorphism due to its  deficiency In
sub population (3% of caucasions  and African –American and 17-23%  Asians).
Elimination
After  a  single  oral  or  i.v  dose  of  14  C  –  labeled  Pantoprazole  to  healthy,  normal
metabolizer  volunteers, approximately 71% of the dose was excreted in the urine with 18% 
excreted  in  the  feces  through  bililary  excretion.  There  is  no  excretion  of  unchanged
pantoprazole.
 
          Table No: 6 - Pharmacokinetic parameters of Pantoprazole.
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Parameters Data
C max 2.5µg/ml
t max 2.5 hours
AUC 4.8 µg-hr/ml
Bioavailability 77%
Biological half life 1.0 hours
Volume of distribution 11.0-23.6 L
  Special population 
Geriatic:
         Only  slight to moderate in Pantoprazole  auc 43% and cmax26% were found  in
elderly  volunteers 64-67% yrs of age. After repeated oral  administration, compared with
younger subjects no  dosage adjustment is recommended based on age.
   Gender:
   There is a modest increase in Pantoprazole AUC and Cmax  in women compared to men.
however  weight normalized clearance  values are similar in women and men.no adjustment
is needed based on gender.
  Renal Impairment;
    In patients  with severe renal impairment , Pharmacokinetic parameters  for pantoprazole
were similar  tothose of healthy subjects. no dosage adjustment is necessary in patients  with
renal impairment .
  Hepatic  Impairment:
In  patients  with  mild  to  severe  hepatic  impairment,  maximum  Pantoprazole
conceentration increase  only slightly relative to healthy subjects. although  serum half lifes
increase to 7-9hrs and AUC values increase by 5-7 folds  in hepatic impaired patients,  these
increase were no greater  than those observed  in slow cyp2cyp19 metabolizer.
             These pharmacokinetic changes in hepatic impareid patients results in  minimal
drug  accumulation  following  once  daily  multiple  dose  administration.  no  dosage
adjustment. doses higher than 40mg was not studied in hepatically impaired patients.
Method of administration
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Pantoprazole 40 mg tablets should not be Split, chewed or crushed, and should be swallowed
whole with water either before or during breakfast.
Duodenal ulcer
The  recommended dosage  is  40  mg pantoprazole  daily (1  Pantoprazole  Generics  40  mg
gastro-resistant  tablet).  Duodenal  ulcers  generally heal  within  two weeks.  If  a  two-week
period of treatment is not sufficient, healing will be achieved in almost all cases within a
further two weeks. Consideration should be given to official local  guidance (e.g.  national
recommendations) regarding bacterial resistance and the appropriate use and prescription of
antibacterial agents.
Gastric ulcer and moderate and severe reflux oesophagitis
The recommended dosage  is  40 mg Pantoprazole  daily (1  Pantoprazole Generics  40 mg
gastro-resistant tablet). A four-week period is usually required for the treatment of gastric
ulcers and refluxoesophagitis. If this is not sufficient, healing will usually be achieved within
a further four weeks.
Eradication of Helicobacter pylori (  H. pylori  )
The recommended dose is 40 mg pantoprazole 2 times daily (1 Pantoprazole Generics 40 mg
gastroresistant  tablet  2  times  daily)  in  combination  with  one  of  the  following  three
combinations:
a) amoxicillin 1 g twice daily + clarithromycin 500 mg twice daily
b) clarithromycin 250−500 mg twice daily + metronidazole 400−500 mg twice daily
c) amoxicillin 1 g twice daily + metronidazole 400−500 mg twice daily
The  second  Pantoprazole  tablet  should  be  taken  before  the  evening  meal.  Combination
therapy should be administered for 7 days in most cases but sometimes up to 14 days.
Consideration should be given to  official  local  guidance (e.g.  national  recommendations)
regarding bacterial resistance and the appropriate use and prescription of antibacterial agents.
Zollinger-Ellison-Syndrome and other hypersecretory conditions
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In  the  treatment  of  Zollinger-Ellison  syndrome  and  other  hypersecretory  conditions,  the
initial  dose is 80mg daily (2 Pantoprazole Generics 40 mg gastro-resistant  tablets).  There
after, the dosage can be increased or decreased, as needed using measurements of gastric acid
secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice
daily. A temporary increase of the   dosage above 160 mg Pantoprazole is possible but should
not  be  applied  longer  than  required  foradequate  acid  control.  Treatment  duration  in
Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions is not limited
and  should  be  adapted  according  to  clinical  needs.In  patients  with  Zollinger-Ellison
Syndrome and other pathological hypersecretory conditions requiring long-term treatment,
Pantoprazole,  as  all  acid-blocking  medicines,  may  reduce  the  absorption  of  vitamin  B1
(cyanocobalamin)  due  to  achlorhydria.  This  should  be  considered  if  respective  clinical
symptoms are observed.
Elderly   
A daily dose of 40 mg pantoprazole should not be exceeded except in eradication treatment of
H.pylori, where elderly patients should receive the standard pantoprazole dose  (2 × 40 
mg/day) during one-week treatment.
Patients with renal impairment
The daily dose of 40 mg Pantoprazole should not be exceeded in patients with impaired renal
function.For this reason, H. pylori triple therapy is not appropriate in these patients.
Patients with hepatic impairment
Patients with severe hepatic impairment should be given 40 mg of Pantoprazole every other
day. In these patients, hepatic enzyme levels should be monitored during the treatment. If
hepatic enzyme levels become elevated, treatment with Pantoprazole should be discontinued.
For this reason, H. pylori triple therapy is not appropriate in these patients.
Children
There is no information on the use of pantoprazole in children. Therefore pantoprazole tablets
should not be used in children.
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Drug –Drug Interactions
               Pantoprazole is metabolized mainly by cyps 3a4,2ds,and 2c9. Invivo drug-drug
interactions  studies  with  cyp2c19.substrates.Nifidepine,  diclofenac,and   theophyline  in
healthy  subjects.  The  pharmacokinetics  of  Pantoprazole  were  not  significantly  altered.
Invivo studies also suggest  that pantoprazole does not  significantly affect  the kinetics  of
the other  drugs  cisapride,  theophyline,  diazepham, phenytoin,  warfarin,  carbamazepine,
clarithromycin, oral contraceptives metabolized by these iso enzymes cyps2c19, 3a4,2c9, 
2ds,  and  1a2  there  pantopazole  doesnot  affect  the  pharmacokinetic  of  other  drugs
metabolized by these iso enzymes.                 
  Interference with Antiretroviral Therapy 
Concomitant use of atazanavir or nelfinavir with proton pump inhibitors is not recommended.
Coadministration  of  atazanavir  or  nelfinavir  with  proton  pump  inhibitors  is  expected  to
substantially decrease atazanavir or nelfinavir plasma concentrations and may result in a loss
of therapeutic effect and development of drug resistance. 
 Coumarin Anticoagulants
There have been postmarketing reports of increased INR and prothrombin time in patients
receiving proton pump inhibitors, including Pantoprazole sodium delayed-release tablets, and
warfarin  concomitantly.  Increases  in  INR  and  prothrombin  time  may  lead  to  abnormal
bleeding  and  even  death.  Patients  treated  with  proton  pump  inhibitors  and  warfarin
concomitantly should be monitored for increases in INR and prothrombin time. 
 Drugs for Which Gastric pH Can Affect Bioavailability
Pantoprazole causes long-lasting inhibition of gastric acid secretion. Therefore, pantoprazole 
may interfere with absorption of drugs where gastric pH is an important determinant of their 
bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). Possible delayed proton 
pump inhibitor absorption and decreased bioavailability by the use  of sucralfate.  Administer 
proton pump inhibitor at least before 30 mins.
 
Adverse Effects
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The most common side effects with Pantoprazole sodium in adults include:
• Headache
• Diarrhea
• Nausea
• Stomach pain
• Vomiting
• Gas
• Dizziness
• Pain in your joints
The most common side effects with Pantoprazole sodium in children include:
• Upper respiratory infection
• Headache
• Fever
• Diarrhea
• Vomiting
• Rash
• Stomach pain
People who are taking multiple daily doses of proton pump inhibitor medicines for a long
period of time may have an increased risk of fractures of the hip, wrist or spine.
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6.1. Excipient Profile: 48
6.1.1. Microcrystalline Cellulose
• Synonyms:
       Avicel PH, celex, cellulose gel, hellulosum microcrystallinum, Emcocel,
Fibrocel, Pharmacel, Vivapur.
• Structural formula:
• Empirical formula:
                               (C6H10O5)n  ,   where n =220.
• Molecular weight:      Approx. 36000
• Description:
It  is  a  purified,  partially  depolymerised  cellulose  that  occurs  as  a  white,
odourless,  tasteless,  crystalline  powder  composed  of  porous  particles.  It  is
commercially available in different particle sizes and moisture grades that have
different properties and applications.
• Functional category:
       Adsorbent; suspending agent; tablet and capsule diluent; and tablet           
          disintegrant.
• Typical properties:
 pH – 5.0 to 7.5
 Density – 1.512 to 1.668 g/cm3
 Angle of  repose – 34.4˚         
• Solubility:
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Slightly  soluble  in  5%  w/v  sodium  hydroxide  solution;  practically
insoluble in water, dilute acids, and most organic solvents.
• Pharmaceutical applications:
• Incompatibilities:  
Incompatible with 
strong oxidizing agents.
• Safety:
Microcrystalline
cellulose  is widely used in oral
pharmaceutical
formulations and        food
products and is generally  regarded
as  a  relatively nontoxic  and
nonirritant material.
Microcrystalline cellulose is not absorbed systemically following oral administration and
thus has little toxic potential. Consumption of large quantities of cellulose may have a
laxative effect, although this is unlikely to be a problem when cellulose is used as an
excipient in pharmaceutical formulations. 
Deliberate  abuse  of  formulations  containing  cellulose,  either  by  inhalation  or  by
injection, has resulted in the formation of cellulose granulomas.
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Use Concentration (%)
Adsorbent 20-90
Antiadherent 5-20
Capsule binder/diluents 20-90
Tablet disintegrant 5-15
Tablet binder/diluents 20-90
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6.1.2. Mannitol
                           
• Synonyms  :      cordycepic acid ,pearlitol
• Chemical name :  D-mannitol
• Emprical formula :  C6 H14 O6
• Molecular weight : 182.17
• Description :
  It is a hexa hydric alcohol related to mannose,mannitol occurs as a white odourless, 
crystalline powder, it has a sweet taste, approximately as sweet as glucose and half  as
sweet as sucrose
• Typical properties :
 Density (bulk):  0.430 g/cm3 for powder;
                                                        0.7 g/cm3 for granules.
 Density (tapped):  0.734 g/cm3 for powder;
                                                           0.8 g/cm3 for granules.
 Density(true ) :      1.514 g/cm3
• Solubility :  Freely soluble in alkalis, water ,insoluble with ether.
• Storage  : Mannitol is stable in the dry state and in aqueos solutions, the bulk material 
should be stored in a well closed container, in a dry place.
• Application : It is primarily used as a diluents (10-90 % )
• Incompatibilities  : Mannitol is in compatible with xylitol infusion and may form a
complexes with some metals  such as aluminium, copper , and iron. reducing sugars
impurities in mannitol have been implicated in the oxidative degradation of a peptide
in a lyophilized formation.
               
6.1.4. Povidone
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• Synonyms  :   Kollidon, Poly [1-(2-oxo-1-pyrrolidinyl) ethylene], polyvidone,     
polyvinylpyrrolidone,povidonum, Povipharm, PVP, 1- vinyl-2-pyrrolidinone    
• Chemical structure :
                                                              
• Molecular Weight  :   2500–3000000
• Description   :  
 Povidone  occurs  as  a  fine,  white  to  creamy-white  colored,  odorless  or  almost
odorless, hygroscopic powder. 
• Solubility   :
                    Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol and           
                    water. Practically insoluble in ether, hydrocarbon and mineral oil. 
• Functional Category  :
                Disintegrant, dissolution enhancer, suspending agent and  tablet binder.
• Applications   :
 In  tableting,  povidone  solutions  are  used  as  binders  in  wet-granulation
processes.
  It is used as a solubilizer in oral and parenteral formulations. 
 Povidone solutions may also be used as coating agents or as binders
  The solubility of a number of poorly soluble active drugs may be increased by
mixing with povidone.
6.1.5. Crospovidone
• Synonyms  :  Kollidon cl; polyplasdone XL. 
• Chemical name : 1-ethenyl-2-pyrrolidinone homopolymer
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• Empirical formula :  (C6H9NO )n
• Molecular weight  : ≥ 1000000
• Description :
            Cros povidone is a white to creamy white , finely divided ,free flowing ,     
practically taste less , odourless , hygroscopic powder
• Typical Properties:
 Acidity/alkalinity: pH = 5.0–8.0 (1% w/v aqueous slurry)
 Moisture content: maximum moisture sorption is approximately60%.
 Particle size distribution: less than 400 mm for PolyplasdoneXL; less than 74 
mm for Polyplasdone XL-10. Approximately50% greater than 50 mm and 
maximum of 3%greater than 250 mm in size for Kollidon CL. Minimum of
                        90% of particles are below 15 mm for Kollidon CL-M.
 Density : 1.22 g /cm2
 Solubility : practically insoluble in water and common organic solvents
• Functional category : Tablet disintegrant
• Storage  :  Cros povidone is stable .however , since it is hygroscopic it should be 
stored in a cool , dry place.
• Application :  
 Cros povidone is a water insoluble tablet dis integrant used at 2-5%          
concentration. 
 It  is  rapidly  exhibits  high  capillary  activity  and  pronounced  hydration
capacity with little tendency to form gels.                          
       
6.1.6. Magnesium Stearate
• Synonyms: Dibasic magnesium stearate, magnesium distearate, Synpro 90.
• Chemical structure:
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• Empirical formula:      C36H70MgO4
• Molecular weight:       591.24
• Structural formula:      [CH3(CH2)16COO]2Mg
• Description:
  A very fine,  light  white,  precipitated or milled,  impalatable powder of low bulk
density, with a faint odour of stearic acid and a characteristic taste. The powder is
greasy to touch and readily adheres to the skin.
• Functional category:    Tablet and capsule lubricant.
• Solubility:  Practically insoluble in ethanol, ethanol (95%), ether and water; slightly
soluble in warm benzene and warm ethanol (95%).
• Typical properties:
 True density – 1.092 g/cm3
 Flowability – Poor flowing, cohesive  powder
 Melting point – 117 to 150˚c
 Loss on drying - ≤ 6.0%
• Pharmaceutical Applications:
            Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical  
            formulations. It is primarily used as lubricant in capsule and tablet manufacture   
             at concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams.
• Safety:   Oral consumption of large quantities may result in some laxative effect or
mucosal irritation.
• Incompatibilities:
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Incompatible  with  strong  acids,  alkalis  and  iron  salts.  Avoid  mixing  with  strong
oxidizing  materials.  Magnesium  stearate  cannot  be  used  in  products  containing
aspirin, some vitamins, and most alkaloidal salts.
 
 
6.1.7. Colloidal Silicon Dioxide
• Synonyms:    Avicel,cellulose gel,aerosol, fumed silica
• Emprical formula:  SIO2
• Molecular weight:  60.08
• D  escription  : 
                  Colloial silicon dioxide is a sub microscopic fumed silica with a particle size of   
                  about 15 nm. It is a light , loose , bluish white coloured , odour less,taste less,        
                  non gritty amorphous powder.
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• Solubility:  Pratically insoluble in prganic solvent , water and acids, except HF, in 
                   Soluble in hot solution of alkali hydroxide
• Typical Properties  : 
 Density (bulk): 0.029–0.042 g/cm3
 Flowability: 35.52% (Carr compressibility index)
 Moisture content:   ≤ 0.25% as per USP Nf 23      
 Particle size distribution: 7–16 nm
 Refractive index: 1.46
 Specific gravity: 2.2
• Functionl category : 
Adsorbent , anticaking agent ,glident, suspending agent , tablet disintegrant,           
viscosity increasing agent .
• Storage :
 Cso is a hygrosopic , but absorbs large quantities of water  with out liquefying. It is 
stored in well closed container.
• Application : It is primarily used as an glident in tablet formulation,and it is used as 
thxotrophic and suspending agent  in gels and semisolid preparation, it also used as 
tablet disintegrants, additionally it is used as dispersing agent for liquids.
6.1.8. Polymethacrylates( Eudrajit L 30 D 55 ) 48,49
• Synonyms  :
 Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit; Kollicoat
                         MAE 30 D; Kollicoat MAE 30 DP; .Eudrajit L30 D55.
• Chemical Name  :
   Poly (methacrylic acid, ethyl acrylate) 1 : 1 aqueous dispersion
• Molecular Weight  : 250 000
• Structural formula :
                                                 
                                                                     CH3
                                                                      
                                        
                                     CH2      C        CH2       CH
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                                  C=O                  C=O
                                    
                                                        OH                    O C2H5
• Description :
              Eudragit L-30 D-55, is an aqueous dispersion of an anionic copolymer based on
methacrylic  acid  and  ethyl  acrylate.  The  copolymer  corresponds  to  USPNF  23
methacrylic acid copolymer,Type C. The ratio of free-carboxyl groups to ester groups is
1 :  1. Films prepared from the copolymers dissolve above pH5.5,  forming salts  with
alkalis, thus  affording coatings that  are insoluble in gastric media but soluble in the
small intestine. Milky-white liquid of low viscosity with a faint characteristic odour.
• Functional Category : Film former; tablet binder; tablet diluent Release retardant.
• Solubility: The dispersion is miscible with water in any proportion, the milky-white 
appearance being retained.A clear or slightly cloudy, viscous solution is obtained by 
mixing 1 part Eudrajit L 30 D-55 with 5 parts acetone. The same results are obtained
by mixing with ethanol or isopropyl alcohol; initially,the polymer is precipitated, but 
            then dissolves again in the excess organic solvent.A clear or slightly cloudy liquid is 
           obtained by mixing 1 part Eudrajit L 30 D-55 with 2 parts 1 N sodium hydroxide.
• Typical Properties ;
 Acid value: 300–330
 True density : 1.062–1.072 g/cm3 
 Viscosity  : 415 mPas
 pH  : 2.1 - 3.0
 Relative density :  1.062 - 1.072
• Pharmaceutical application :
                     Eudragit L 30 D-55 is used as an enteric coating film former  solid-dosageforms.
                     The coating is resistant to gastric juice but dissolves readily at above pH 5.5.
• Stability and Storage Conditions   :
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Dispersions are sensitive to extreme temperatures and phase  separation occurs below
8C. Dispersions should therefore be stored at temperatures between 5 and 2580C and
are stable for at   least 18 months after shipping from the manufacturer’s
           warehouse if stored in a tightly closed container at the above conditions.
• Safety :
Polymethacrylate  copolymers  are  widely  used  as  film-coatingmaterials  in    oral
pharmaceutical  formulations.  They  are  alsoused  in  topical  formulations  and  are
generally regarded as nontoxic and non irritant materials. A daily intake of            2mg
/kg body weight  of  Eudragit (equivalent  to  approximately 150mg for  an  average
adult)  maybe regarded as   safe in humans.
• Application :
                             Eudragit L 30 D-55 is used as an enteric coating film former
                             for solid-dosage forms. The coating is resistant to gastric juice
                             but dissolves readily at above pH 5.5.
6.1.9. Hydroxypropyl methylcellulose
• Non-proprietary names:  Hypromellose (BP, JP, PhEur, USP)
• Synonyms: 
         Benecel  MHPC  E464;  Hydroxypropyl  methylcellulose  HPMC;
Hypromellosum; Methocel; Methylcellulose propylene glycol ether; Metolose;
Pharmacoat; Tylose MO.
• Structural formula:
• Molecular weight:
          Approx. 10000 to 1500000.
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• Description:   
         Hypromellose is  an odourless and tasteless,  white or  creamy-white
fibrous or granular powder.
• Functional category:
        Bioadhesive material; coating agent; controlled-release agent; dispersing
agent;  dissolution  enhancer;  emulsifying  agent;  emulsion  stabilizer;
extended-release  agent;  film-forming agent;  foaming agent;  granulation  aid;
modified-release  agent;  mucoadhesive;  solubilising  agent;  stabilizing  agent,
suspending  agent;  sustained-release  agent;  tablet  binder;  thickening  agent;
viscosity-increasing agent.
• Solubility:
         Soluble in cold water; practically insoluble in hot water, chloroform,
ethanol  (95%),  and  ether;  but  soluble  in  mixtures  of  ethanol  and
dichloromethane and mixtures of methanol and dichloromethane and mixtures
of water and alcohol.
• Typical properties:
 pH (for a 2%w/w aqueous solution) – 5.0 to 8.0
 Melting point – browns at 190-200˚c; chars at 225-230˚c.
 Glass transition temperature – 170-180˚c.
 Specific gravity – 1.26
 Loss on drying - ≤5.0%
 Nominal viscosities (mPa s) - 3 - 100000 (2%w/w solution at 20oC
• Pharmaceutical applications:
Solid oral dosage forms
i) As tablet binder in either wet or dry granulations
(2-5%w/w).
ii) High  viscosity  grades  as  matrix  formers  for
sustained drug release (10-80%w/w).
iii) Depending on viscosity grade, concentrations of
2-20%w/w are used for film-forming solutions to
coat tablets.
iv) Lower viscosity grade – aqueous film coating.
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v) Higher viscosity grade – Nonaqueous coating.
Liquid oral dosage 
forms
As suspending or thickening agents at concentrations 
of 0.25 o 5.0%.
Ophthalmic preparations Thickening agent to vehicles for eye drops and 
artificial tear solutions (0.45 to 1.0%).
Nasal preparations At a concentration of 0.1%.
Topical preparations As an emulsifier, suspending agent and stabilizing 
agent in topical gels and ointments.
                                                     
6.2.0. Propylene glycol
• Synonyms :     Dihydroxypropane, 2-hydroxypropanol, methyl  ethylene glycol,         
methyl  glycol, propane-1,2-diol.
• Chemical name  :         1,2-Propanediol 
Empirical formula :    C3H8O2 
• Molecular weight  :       76.09
• Description  : Propylene glycol is a clear, colorless, viscous, practically odorless
                                    liquid  with a  sweet, slightly acrid taste resembling that of glycerin.
• Typical properties:    
         
 Boiling point:
 Density: 1.038 g/cm3 at 200C
 Melting point: -590C 

• Solubility  :                              
         miscible with acetone, chloroform, ethanol   (95%),glycerin, and water;         
         soluble at 1 in 6 parts of ether;Not miscible with light mineral oil or fixed 
         oils, but will  Dissolve some essential oils.
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• Functional Category   :  Antimicrobial preservative; disinfectant; humectant
                                                   solvent; stabilizer for vitamins. Plasticizer.
• Applications :         
 
 Propylene glycol has become widely used as a solvent.
 
 preservative in a variety of parenteral and non parenteral            
pharmaceutical formulations.
 As an antiseptic it is similar to ethanol, and against molds it
                                     is similar to glycerin and only slightly less effective than  ethanol.
6.2.1. Triethyl Citrate
• Synonyms:  Citric acid, ethyl ester;  Citroflex 2;  Citrofol  AI;  E1505;Hydagen CAT;
TEC.
• Empirical Formula :   C12H2O7
• Molecular Weight : 276.29   
                               
• Chemical Name: 2-Hydroxy-1,2,3-propanetricarboxylic acid, triethyl ester.
• Description : Triethyl citrate is a clear, odorless, practically colorless, Oily liquid.
• Functional Category: Plasticizer.
• Typical Properties:
 Acid value: 0.02
 Boiling point: 2888C (decomposes)
 Flash point: 1558C
 Viscosity (dynamic): 35.2 mPa s (35.2 cP) at 258C
• Solubility:  soluble 1 in 125 of  peanut oil,  1 in 15 of  water.Miscible with ethanol
(95%), acetone, and propan-2-ol.
• Applications:
 Used to plasticize polymers in formulated pharmaceutical coatings.The
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                               coating applications include capsules, tablets, beads, and granules for taste
                                masking, immediate release, sustained release, and enteric formulations.
 Triethyl citrate is also used as a direct food additive for
                              flavoring, for solvency, and as a surface active agent.
    
6.2.2.  Titanium  dioxide 
• Synonyms :   Anatase titanium dioxide; brookite titanium dioxide; color
• Empirical Formula :   TiO2 
• Molecular Weight:   79.88
• Description :
                    White, amorphous, odorless, and tasteless non hygroscopic powder. Although
the  average  particle  size  of  titanium dioxide  powder  is  less  than  1  mm,  commercial
titanium  dioxide  generally  occurs  as  aggregated  particles  of  approximately100  mm
diameter. 
• Typical Properties   :
 Density (bulk): 0.4–0.62 g/cm3
 Density (tapped): 0.625–0.830 g/cm
 Density (true):3.8–4.1 g/cm3 
 Melting point: 18558C
 Moisture content:  0.44%
 Refractive index: 2.55 
            
• Solubility: 
             Practically insoluble in dilute sulfuric acid, hydrochloricacid, nitric acid, organic
solvents,  and  water.  Solublein  hydrofluoric  acid  and  hot  concentrated  sulfuric  acid.
Solubility depends on previous heat treatment; prolongedheating produces a less-soluble
material.
• Functional Category  :  Coating agent, Opacifier,  Pigment.
• Applications: 
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 Titanium dioxide is widely used in confectionery, cosmetics and foods, in
the plastics industry, and in topical and oral pharmaceutical formulations as
white pigment.
  Titanium  dioxide is used as a white pigment in film-coating suspensions,
sugar-coated tablets, and gelatin capsules.
6.2.2. Diethyl phthalate 
• Synonyms  :   DEP; ethyl benzene-1,2-dicarboxylate; ethyl phthalate; Kodaflex
                                  DEP; phthalic acid diethyl ester.
• Chemical Name :  1,2-Benzenedicarboxylic acid, diethyl ester .
• Empirical Formula :  C12H14O4
• Molecular Weight :   222.24
• Description :
            Diethyl phthalate is a clear, colorless, oily liquid. It is practically  odorless,with a
            Very slight aromatic odor and a bitter, disagreeable taste.
• Typical Properties :
 Boiling point: 2958C
 Flash point: 1608C (open cup)
 Melting point: 408C
 Refractive index: 25 = 1.501
 Specific gravity: 1.120 at 258C
• Solubility:   Miscible with ethanol (95%), ether, and many other organic solvents 
                     practically insoluble in water.
• Functional Category : Film-former; plasticizer; solvent.
• Applications  :
 Diethyl  phthalate  is  used  as  a  plasticizer  for  film  coatings  tablets,
beads, and granules at concentrations of 10–30% by weight of polymer.
 Diethyl phthalate is also used as an alcohol denaturant.
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7. METHODOLOGY
7.1. Preformulation studies:
Preformulation  is  usually  defined  as  the  science  of  investigation  of  Physio-Chemical
properties of a drug substance alone and when combined with excipients. Since tablets and
capsules account for approximately 70% of pharmaceutical preparations, it is important to
undertake  an  investigation  into  the  solid-state  properties  of  candidate  drugs  during
preformulation. 
The basic purpose of the Preformulation activity is to provide a rational basis for the
formulation approaches, to minimize the    chances of success in formulating an  acceptable
product  and  to  ultimately  provide  a  basis  for  optimizing  drug  product  quality  and
performance. The first step in any formulation activity is careful consideration of a complete
physicochemical profile of the active ingredients available, prior to initiating a formulation
development activity.50 
7.1.1. Evaluation of API
            The Evaluation of Pantoprazole sodium was done according to USP.
Following are some of the important parameters evaluated during preformulation studies
and results are tabulated in Table No: 17 to 19.
 Raw material analysis of  Pantoprazole sodium  : 51
• Appearance: white to off white crystaline powder.
• Solubility studies :
Pantoprazole sodium is classified under class III according to BCS i.e; highly soluble
but low permeable. Solubility studies were conducted at all pH ranges from 1 to 12. The
solubility of API was determined by dissolving the highest unit dose of the drug in 250
mL of  like water,  acetone, chloroform, n-hexane Highest dose of the drug i.e., 45.1mg
was dissolved in 250 mL of medium and was kept untouched for 12 hrs. Later  the
insoluble drug was filtered off and the solution was analysed by HPLC technique to
find out the solubility.
• Assay of  Pantoprazole sodium :  (HPLC METHOD )
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Preparation of Buffer solution : Dissolved  1.74 g of dibasic potassium phosphate in 1000
ml  of water and adjusted with a solution of phosphoric acid to a pH of 7.0.
Diluent: Prepared a mixture of acetonitrile and 0.001 N sodium hydroxide solution (50:50).
Mobile phase: A filtered and degassed mixture of  buffer solution and acetonitrile.
     Preparation of Standard solution :
 45.1 mg of  Pantoprazole sodium RS was weighed accurately and then transferred  into
100 ml  volumetric flask. To this 50 ml of 0.001 N sodium hydroxide  was added Then it
was shaken and sonicated for 5 mins  to dissolve the content. and make up the volume with
diluent. from this 3.4 ml was pipette out  and transferred to 50 ml volumetric flask. and
make up the volume with diluent.
     Preparation of Sample solution:
 45.1 mg of Pantoprazole sodium was weighed accurately and then transferred into 100 ml   
volumetric flask. To this 60 ml of 0.001 N sodium hydroxide  was added Then it was shaken
and sonicated for 10 mins to dissolve the content. and make up the volume with diluent.
Chromatographic Condition
• Apparatus     :         HPLC
• Coloumn        :       (4.0mm X 25cm) coloumn, that contains 5-µm packing L1
• Flow rate        :       1ml/min
• Coloumn temp  :      400 C
• Wave length    :       290 nm
• Inj volume      :        20µl  
   
Procedure:
20 µl of filtered portion of the standard preparation (five injections and sample preparation
were  separately  injected  into  the  chromatographic  system.  The  chromatograms   was
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recorded  and  the  responses  were  measured  for  the  major  peaks.  Then  calculated  the
percentage of  impurities in the portion of pantoprazole sodium by using the following
expression.
       Evaluation of system suitability:
The  coloumn efficiency as  determined for  the   Pantoprazole peak   from the  standard
preparation is not less than 2000 theoretical plates and the tailing factor  for the same peak
is  not  more than 2.0.  the The percentage relative standard deviation for  five replicate
injections is not more than 5.0%. The reporting level for impurities is 0.05%.    
  
7.1.2. Drug-Excipient compatibility studies : 52 
In  the  tablet  dosage  form  the  drug  is  in  intimate  contact  with  one  or  more
excipients; the latter could affect the stability of the drug.  Knowledge of drug- excipient
interactions is therefore very useful to the formulator in selecting appropriate excipients.
This   information may be present for known drugs. For new drugs or new excipients, the
preformulation scientist must generate the needed information.
 Physical studies:
Active ingredient was mixed well with all excipients in binary ratio and small portion of
this mixed powder was placed in a 2 ml of cleaned and dried vial (USP Type I). This vial
was  kept  for  observation  in  stability  chamber  at  40oC  ±  2oC/  75 ± 5%  RH.  Physical
observation has been carried out visually at the initial stage and after 30 days exposure to
the stated conditions. The results were   tabulated in Table No:20.     
 FT-IR studies :
Physical compatibility studies were assured by FT-IR studies. The crude drug sample, drug-
excipient mixtures of the formulation were chosen for the study. The FT-IR        spectra’s of
the above samples were studied after a period of 30 days from preparation of the mixtures,
to facilitate prompt detection of incompatibility.  The spectra’s were         obtained by
preparing Potassium bromide pellets under dry condition by using pellet press.The spectra
of the crude drug sample and that of the drug-excipient mixtures were     compared to check
the incompatibility problems. The FT-IR spectra’s were shown in Fig. 6 to Fig 13.
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TableNo:7- Protocol For Drug-Excipient Compatibility Studies
S.No
    
        Drug and excipients Ratio 
1 Drug alone -
2 Drug  + Mannitol 1:2
3 Drug + Crospovidone 2:1
4 Drug + Povidone + Sodium carbonate 5:1:1
5 Drug + MCC pH112 2:1
6 Drug + Aerosil 10:1
7 Drug + Magnesium Stearate 10:1
7.2. Formulation of Pantoprazole sodium delayed release tablet :
 Conversion Factor Calculation  :
Molecular weight of  Pantoprazole sodium sesquihydrate   =  432.37
Molecular weight of Pantoprazole           = 383.37
Conversion factor   = 432.37 / 383.37 = 1.127
40mg Pantoprazole per tablet is the required label claim.
     Thus, amount of Pantoprazole  Sodium Sesquihydrate equivalent to 40 mg  of 
     Pantoprazole =  40*1.127 =  45.11mg.
 Selection of Process :
Micrometric Studies has been carried out for the Pantoprazole sodium. based on the results it
was concluded that the drug is not suitable for direct compression method due to fine particle
size and poor flow characteristics. So, the Delayed release tablet of Pantoprazole sodium was
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prepared  by wet  granulation  technique.  All  tablet  ingredients  was  accurately  weighed  as
mentioned in Table No:8.  The Average weight of each core tablet was set to 150 mg in all
trails taken. 
Table No: 8 -  Formulation Trials
Formula for Preparation of Pantoprazole Sodium Core Tablet
S.No     Ingredient (mg)
Formulation code
F1 F2 F3 F4 F5
             Core Formulation
1 Pantoprazole  sodium 
sesquihydrate
45.11 45.11 45.11 45.11 45.11
2 Mannitol 90.59 70.00 70.00 65.00 63.00
3 Crospovidone 8.00 8.00 8.00 13.00 15.00
4 Sodium carbonate 1.60 1.60 1.60 1.60 1.60
5 Povidone 3.20 3.20 3.20 3.20 3.20
6 Purified water Q.S Q.S Q.S Q.S Q.S
7 MCC pH 112 - 20.44 20.44 20.44 20.44
8 Aerosil - 0.15 0.15 0.15 0.15
9 Magnesium stearate 1.50 1.50 1.50 1.50 1.50
             
       Total weight (mg) 150 150 150 150 150
                   
7.3. Coating Formula:
        3% seal coating has  been given for all the three formulation F3,F4,F5 To prevent direct
        interaction between pantoprazole sodium and Eudrajit Polymer.
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                        Table  No: 9 - Composition of  Ingredient For Seal Coating 
S.No      Ingredient      Quantity( gm )
    1 HPMC 15 cps 10
    2
 
Titanium oxide 7.0
    3
   
Propylene glycol 1.0
    4
     
 Purified water Q.S
7.3.1. Preparation of seal coating solution:
Weighed  accurately   a  required  quantity  of  HPMC 15  cps   and  soaked  in  water  for
30 mins, and  stirred until it swells. Mean while  titanium dioxide was Triturated in a motar
and added to the solution and stirred. followed by  propylene glycol to the solution and
stirred. Finally the volume were make up to required quantity with purified water. Filtered
the above solution with #100 mesh.
7.3.2. Weight Built up calculation for Seal coating: [  3% ]
                      150 x 3 %  ( 3gm            100 ml )  0.03 = 4.5 mg
                      150 + 4.5  = 154.5 mg   
                  The weight of seal coated tablet   =   154.5 mg.
            
     Table No:10 - Composition of  Ingredient For  Enteric Coating
       12%  seal coating has been given for all the three formulation F3,F4,F5 to protect the drug 
from acidic environment.
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S.No       Ingredient  
Quantity ( gm )
F3 F4 F5
1 Eudrajit L30 D55 92.00 92.00 92.00
2 Diethyl Phthalate 14.40 14.40 -
3 Titanium dioxide 16.60 16.60 16.60
4 Triethyl citrate - - 14.40
5 Purified Talc 23.00 23.00 23.00
6 Ferric oxide 2.00 2.00 2.00
7 Purified water Q.S Q.S Q.S
7.3.4. Preparation of  Enteric Coating solution:
     A required quantity of Methacrylic acid copolymer dispersion, was weighed accurately and
stirred until it swells. Mean while plasticizer, titanium dioxide, purified talc and ferric oxide
were  triturated separately in a motar. and added to the solution and stirred. Finally the volume
were make up to required quantity with purified water.  Filtered the above solution with #100
mesh.
7.3.5. Weight Built up calculation for enteric coating : [  12 % ]
154.5 x 12% (12 gm  100ml) 0.12 =18.54 mg
154.5 + 18.54   =  173.04 mg
                 The weight of enteric coated tablet = 173.04mg.  
             Table No:11 -  Operation Condition For  Seal and Enteric Coating Process
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7.4.
 TRIAL I
 Accurately weighed the specified quantity of ingredients – Pantoprazole sodium,  Mannitol,
Crospovidone. and the above  materials were Sifted through  #30 mesh and placed in a separate
polythene bag and they  are used as dry mix .
 Preparation of Binder solution :
             Purified water was taken in a SS Vessel. To this Povidone was added and Stirred to  get  a       
             clear solution. Sodium carbonate was added into the solution and kept under stirring condition
 and used as binder solution.
     [Notification : Na2co3  monohydrate is added with povidone,  because povidone  is  in 
     Acidic  pH when it is added as binder solution , the drug which is  unstable  in the  gastric 
     condition  (Acidic  pH ) will be degraded. So to avoid that  Sodium carbonate is   added  to  
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         Specifications 
                      Range      
      Seal coating Enteric  coating
      
       Pan diameter 
                
            12”
       
           12”
        
       Speed of pan revolution
            
       8-10 rpm
    
         10-12 rpm        
       
       Distance of spray gun
            
          5-6”
     
            5-6”
       
       Spray nozzle diameter
         
          1.2 mm
     
           1.2 mm
         
       Spray rate 
     
    2.5-3 ml /min
     
        1.5 -2.0 ml /min
      
       Dry air temperature 
   
  50  ± 5/ 30 mins
   
     50  ± 50C / 30 mins
         
       Coating time 
          
      2 hours
          
     4 hours
       Bed temperature       30-400C        30-400C
Methodology
     maintain  in  Alkaline pH.
               The sifted materials were mixed for 5 mins in a poly bag before granulating  and transferred  
                to  a vessel  and granulated with required quantity of  binder solution  by   kneading method  
                and the granules were dried in hot air oven at 500C.  then semi dried granules were   passed  
                through sieve No. 20, and continued the drying  till the  moisture content of granules  is less 
                than 1.0 %. Then after obtaining the optimum moist content,  granules  were removed  from 
                the oven.  and  the the size of granules were reduced to get  uniform particle size.  and    the  
    above granules were mixed with  Crospovidone.  and  sifted  through  #60 mesh for 5 mins,  
    in a polybag.   Finally lubricated with required quantity  of  magnesium stearate after sifting 
     it through # 60mesh for 5 min. and the lubricated granules  was then compressed into tablets
                with an average  weight of 150 mg  using  8.00 mm punches.
   
TRIAL  I I
Same  as  procedure  of  trial  1.  but  in  this  formulation  the  concentration  of  Mannitol  was
decreased to 70 mg/unit. MCC pH 112 was included as diluent in the Extra granular portion of
the formulation, because of its less  moisture content. Aerosil  was also included to improve the
flow property of the granules. Further trial has been taken as scale up of trail 2.
TRIAL  I I I
In trail 3 the core tablets were coated with seal coating solution with an average weight  built
up of 3%. these seal coated tablets were further coated with enteric coating solution with an
average weight built up of 8, 10,12%.
TRIAL   IV
In trial 4 the concentration of Mannitol is further decreased to 65mg/unit and increasing the
Crospovidone concentration to 13mg/unit.
TRIAL   V
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In  trail  5  the  concentration  of  Mannitol  is  still  decreased  to  63mg/unit  and increasing the
Crospovidone concentration to 15mg/unit. diethyl phthalate was replaced with triethyl citrate in
the enteric coating part, to give better flexibility to the polymer.
7.5. Evaluation of  Precompression Parameters:
The characteristics of a tablet that make it a popular dosage form, e.g. compactness, physical
stability,  rapid production capability,  chemical  stability and efficacy are in general  dictated
primarily by the qualities of the granulation from which it is made. Basically stated, materials
intended  for  compaction  into  a  tablet  must  possess  two  characteristics:  Fluidity  and
Compressibility.53 To  a  great  extent  these  properties  are  required  by  the  compression
machine design. Thus good flow properties are a prerequisite for the successful manufacture of
tablets. It  is a property of all powders to resist the differential movement between particles
when subjected to external stresses. This resistance is due to the cohesive forces between the
particles. Tablets require the flow of the correct weight of material into a specific volume, the
behaviour of the material under pressure is important; and the wetting of the powder is also
critical for granulation and subsequent disintegration and dissolution of the dosage form. 
7.5.1. Bulk density:
Bulk density is a characteristic of  a powder rather than individual particles and is given by
the  mass,  M,  of  the  powder  occupying  a  known  volume,  Vo. It  is  expressed  in  g/ml.  An
accurately weighed quantity of granules was transferred into a 50 ml measuring cylinder with
the aid of the funnel. The unsettled apparent volume, to the nearest graduated unit occupied by
the granules was measured. Bulk density was determined using the formula 54,
ρbulk = m/Vo
           Where,
               ρbulk = Bulk density;
               m  = Mass of the blend 
              Vo = Untapped Volume
7.5.2. Tapped density:
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Tapped density is achieved by mechanically tapping a measuring cylinder containing a powder
sample. After observing the initial volume, the cylinder is mechanically tapped, and volume
readings are taken until little further volume change is observed.54  The measuring cylinder
containing a weighed quantity of granules (after measurement of bulk density) was subjected to
500 taps in tapped density tester (Electro Lab USP II). The tapped density was calculated by
using the formula,
ρt
 
= m/Vt
where,
 
ρt = Tapped density; m = Mass of the granules and  Vt = Final tapped volume.
7.5.3. Carr’s compressibility index:
Compressibility index are a measure of the tendency for arch formation and the ease with
which the arches will fail. 55 Table No: 12 shows the relationship between compressibility index
and flowability. It is calculated by using the formula 56,
CI = ρt – ρbulk / ρt × 100
 where,  CI =  Compressibility index; ρbulk = Bulk density and ρt = Tapped density.  
Table No - 12
            
7.5.4. Hausner’s ratio:
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Compressibility index (%) Flow characters
          <   10 Excellent
          11-15 Good
          16-20 Fair
          21-25 Passable
          26-31 Poor
          32-37 Very poor
>38 Very, very poor
Methodology
    Hausner found that the ratio ρt / ρbulk was related to interparticle friction and, as such could be
used to predict powder flow properties. He showed that powders with low interparticle friction,
such as  coarse spheres,  had ratios  of  approximately 1.2;  whereas  more cohesive,  less  free
flowing powders such as flakes have values greater than 1.6.57 Table No: 13 shows the flow
characters and corresponding Hausner’s ratio. It is calculated using the formula 58,
Hausner’s Ratio = ρt / ρbulk
                 where, 
                          ρbulk = Bulk density and ρt  = Tapped density.  
Table No- 13
7.5.5. Angle of repose:
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Flow characters Hausner’s ratio
  Excellent 1.0– 1.11
  Good       1.12 – 1.18
   Fair       1.19 – 1.25
   Passable       1.26 – 1.34
   Poor       1.35 – 1.45
   Very poor        1.46 – 1.59
   Very, Very poor >1.60
Methodology
Angle  of  Repose  (θ)  is  the  maximum angle  between  the  surface  of  a  pile  of  powder and
horizontal  plane.  It  is  usually  determined  by fixed  funnel  method and  is  the  measure  the
flowability of powder/granules. The angle is a measure of the cohesiveness of the powder, as it
represents the point  at  which the interparticle attraction exceeds the gravitational  pull  on a
particle. (59) shows the flow properties and corresponding angle of repose.
Procedure
        Weighed quantity of granules was passed through a funnel kept at a height of 2 cm for the
base. The powder is passed till it forms heap and touches the tip of the funnel. The height of the
heap formed and radius of the base of the heap was measured. Angle of repose was calculated
by using the formula (60),
θ = tan -1(h/r)
             where,  θ = Angle of repose;
              h = height of the heap of pile and r = radius of base of pile. 
                                                  Table No -14
 
7.5.6.  Moisture content:
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Flow properties Angle of repose (degree)
  Excellent 25-30
  Good 31-35
   Fair – aid not needed 36-40
  Passable – may hang up 41-45
   Poor,must agitate 46-55
    Very poor 56-65
   Very, very poor >66
Methodology
A known quantity of granules say 3gm was weighed on the sample pan of the IR moisture
balance.  The  sample  was  dried  until  anhydrous  at  60˚c  by the  use  of  IR  radiation.  The
percentage of moisture content of the granulation can be determined as the end point   display
when all the moisture in the sample has been removed by the radiation.
7.6.  Evaluation of  post-compression parameters:
7.6.1.   Hardness:
Tablets require a certain amount of strength or hardness to withstand mechanical shocks of
handling in manufacture, packaging, and shipping. Tablet hardness has been defined as, the
force required to break a tablet in a diametric compression test. (60) Tablet hardness of all the
formulations was measured using a Monsanto hardness tester.
7.6.2. Thickness:
Tablet  thickness  is  an  important  parameter  to  be  controlled  to  facilitate  packaging.  Tablet
thickness,  at  constant  compressive  load,  varies  with  changes  in  die  fill,  with  particle  size
distribution and packing of the particle mix being compressed; whereas at constant die fill,
thickness varies with variations in compressive load. Tablet thickness must be controlled within
a  ±5% variation  of  a  standard  value.  Any variation  within  a  particular  lot  should  not  be
apparent  to  the  unaided  eye  of  the  consumer. (61) Thickness  of  all  the  formulations  was
measured using a digital vernier  tandar.
7.6.3. Friability:
Friability  is  a  measure  of  the  resistance  of  the  tablet  to  abrasion.  Tablets  are  generally
subjected to a  standardized level of abrasion for a given time and the friability is expressed as
a  %weight  loss.  The measure  is  useful  to  determine  the  ability  of  the  tablet  to  withstand
abrasion during handling,  coating,  packing and transport.  The laboratory friability tester  is
known as the Roche friabilator. This device subjects the tablets to the combined effects of 
abrasion and shock by utilizing a plastic chamber that rotates at 25 rpm, dropping the tablets
form a height of 6 inches with each revolution. (62)
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Twenty tablets were weighed accurately and placed in the friabilator and was operated for 100
revolutions or 4 minutes. The tablets were then de dusted and weighed. The weight loss of 0.5
to 1% is considered as acceptable limits for  conventional uncoated tablets. The weight loss
was calculated using the formula(62) ,
Friability, F (%) = (Weight loss/Initial weight)*100
The friability of the all the formulations was determined as per the above  procedure.
7.6.4. Weight Variation Test: 
Twenty tablets were selected randomly and weighed individually. Calculate average weight and
compare the individual  tablet  weight  to  the  average.  Not  more than  two of  the  individual
weights  deviate from the average weight  by more than the percentage shown in and none
deviate by more than twice the percentage. (63)
                          
Table No - 15
Average weight of
Tablets (mg)
Max. Percentage
deviation (%)
130 or less 10
130 – 324 7.5
324 or more 5
7.6.5. Disintegration test:
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Tablet  disintegration  study  was  performed  for  delayed  release  enteric  coated   tablets  of
pantoprazole sodium. Disintegration time was determined using USP tablet disintegration tester
the study was conducted at  37oC±2˚C for 2 hours in 800 ml 0.1N Hcl (  pH 1.2),  then the
medium was with 800 ml of pH  6.8 phosphate buffer and tested for disintegration for 60 mins. 
7.6.6. Preparation of Standard curve for Pantoprazole sodium in 0.1N Hcl :
Pantoprazole  sodium  was  scanned  from  wave  length  210nm-360  nm  in  UV-Visible
Spectrophotometer. it was found that maximum absorption of the drug (4µg/ml) was found in
λmax 305 nm is given in Table No:25.
45.1 mg of Pantoprazole sodium were accurately weighed and transferred to 100 ml standard
flask, dissolved first in 0.1N sodium hydroxide, using 10% of the final volume & the volume
was make up with pH 6.8 phosphate buffer. From this primary stock solution pipetted out 1ml
and transferred to 100 ml standard flask and made up the volume with 0.1N Hcl (pH 1.2)
medium. this is secondary stock solution, from this  various concentration of drug ( 0, 1, 2, 3,
4, 5 µg/ml) were pipetted out separately into 10 ml standard flask and make up to required
volume  using  0.1N  Hcl.  Their  individual  absorbance  was  readed  using  UV-Visible
Spectrophotometer.  The  Standard  curve  was  prepared  by  plotting  various  concentrations
against respective absorbance .
7.6.7. Preparation  of  Standard  curve  for  Pantoprazole  sodium  in  pH  6.8  phosphate
buffer :
 Pantoprazole  sodium  was  scanned  from  wave  length  210nm-360  nm  in  UV-Visible
Spectrophotometer. it was found that maximum absorption of the drug (23µg/ml) was found in
λmax 288 nm is given in Table No:26.
 45.1 mg of Pantoprazole sodium were accurately weighed and dissolved first in 0.1N sodium
hydroxide,  using 10% of the final volume,  and the volume make up with  pH 6.8 phosphate
buffer.  From this 10 ml  was pipetted out and transferred into 100 ml volumetric flask and
make up to  required volume using pH 6.8 phophate buffer, this is secondary stock solution,
from this  various concentration of drug ( 0, 5, 10, 15, 20, 25, 30µg/ml ) were pipetted out
separately into 10 ml standard flask and make up to required volume using pH 6.8 phophate
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buffer.  Their  individual  absorbance  was  readed  using  UV-Visible  Spectrophotometer.  The
Standard curve was prepared by plotting various concentrations against respective absorbance .
7.6.8. In vitro   dissolution study: 
Dissolution media preparation:  
• Preparation of  0.1N Hcl - 8.5 ml of concentrated Hcl was added to 1000 ml of purified
water and the pH was found to be 1.2.
• Preparation  of  pH 6.8  phosphate  buffer- Dissolved  6.8  g  of  potassium Dihydrogen
phosphate in Purified water. And the volume was make  upto1000 ml with purified water
and adjusted the  pH by using 0.1 N sodium hydroxide solution.
Standard Preparation  for Acid  stage:   Accurately  weighed  and  transferred  45.1  mg  of
Pantoprazole sodium  in 100 ml standard flask,  dissolved first in 0.1 N sodium hydroxide,
using 10% of the final volume & the volume was make up with  pH 6.8 phosphate buffer .
From this primary stock solution pipetted out  1ml  and transferred to 100 ml standard flask
and made up the volume with 0.1N Hcl ( pH 1.2) medium.
Standard  preparation  for  Buffer  stage:  Accurately  weighed   and  transfer  45.1  mg  of
Pantoprazole sodium reference standard in to 100 ml volumetric flask, dissolve first in 0.1N
sodium hydroxide, using 10% of the final volume,  then dilute to  required volume with pH 6.8
phosphate buffer this is primary stock solution. From this 10 ml  was pipette out into 100 ml
volumetric  flask  and  made  upto  required  volume  using  pH  6.8  phophate  buffer  this  is
secondary stock solution, from  this 5 ml was pipette out into 10 ml volumetric flask and made
up to required volume with  pH 6.8 phophate buffer.
Test  procedure: Drug  release  study  was  carried  out  using  USP  dissolution  rate  test
Apparatus-II.  And the study was conducted at  37˚C ± 0.5˚C 100rpm for 2 hrs in 1000 ml
0.1N Hcl of  pH 1.2, and the sample was withdrawn after 2 hr. Then the  dissolution medium
was replaced with 1000 ml of pH 6.8 phophate buffer and the dissolution was carried out upto
45  mins.  An  Aliquots  of  the  dissolution  medium  was  withdrawn  at  the  5,  10,  15,  20,
30, 45 mins time points filtered. 5 ml of the filtrate from each bowl was separately diluted to 10
ml each with dissolution medium. the samples were analyzed with UV-VIS Spectrophotometer
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at  305nm for  0.1N Hcl  and 288 nm for pH 6.8 phosphate buffer. The percentage of  drug
released at each time point was calculated by mentioned formula.
7.6.9. Assay of Enteric coated tablets of Pantoprazole sodium 64 : ( HPLC)
Preparation  of  Buffer  solution:  Dissolved  3.85  g  of  ammonium  acetate  and  1.1  g  of
tetrabutylammonium hydrogen sulfate in 1 L of water, and adjusted with ammonium hydroxide
solution diluted 1 : 1 with water to a  pH  of 7.9. 
Diluent:  A mixture of 0.02 N sodium hydroxide and acetonitrile (1 : 1) was prepared.
Mobile phase: A filtered and degassed mixture of buffer solution and acetonitrile (65 : 35) was
prepared .
Preparation of standard solution :
45.1 mg of Pantoprazole sodium RS was weighed accurately and then transferred into 200 ml
volumetric  flask  60  ml  of  0.02  N  sodium hydroxide  was  added  Then  it  was  shaken  and
sonicated for 5 mins  to dissolve the content.  Add about 2 ml of acetonitrile and made up the
volume with 0.02 N sodium hydroxide to Filtered a portion of this solution through 0.45micron
membrane filter. The filtrate was collected after discarding the first few ml of the filtrate.
Preparation of sample solution:
20 tablets were weighed and powdered,  A quantity of  powdered tablet  equivalent  to about
174 mg of  Pantoprazole sodium  was transferred to 200 ml  and diluents was added to about
60 ml, and the flask was shaked  mechanically for  about 60 mins, and the volume was make
up with 0.02 N sodium hydroxide and acetonitrile (1:1) Then the solution was filtered through
0.45 micron membrane filter. The filtrate was collected in HPLC vial after discarding the first
10ml of the filtrate. 
       Chromatographic Condition
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• Apparatus     :         HPLC
• Coloumn        :       (4.0mm X 25cm)  coloumn, that contains 5-µm packing L1
• Flow rate        :       1ml/min
• Coloumn temp:      Ambient
• Wave length    :       290 nm
• Inj volume      :        20µl
• Detector          :        Photodiode array
Procedure:
20 µl of filtered portion of the standard preparation (five injections and sample preparation
were separately injected into the chromatographic  system. The chromatograms  was recorded
and the responses were measured for the major peaks. The content of Pantoprazole per tablet
was calculated using the following expression.
Evaluation of system suitability:
The coloumn efficiency as determined for the Pantoprazole peak  from the standard preparation
is not less than 2000 theoretical plates and the tailing factor  for the same peak is not more than
2.0.  The  percentage  relative  standard  deviation  for  five  replicate  injections  of  standard
preparation  not more than 2.0.    
7.7. Comparative dissolution profile study: 65
In recent years, FDA has placed more emphasis on a dissolution profile comparison in the area
of  post-approval  changes  and  biowaivers.  Under  appropriate  test  conditions,  a
dissolution profile can characterize the product more precisely than a single point dissolution
test.  A dissolution  profile  comparison  between  pre-change  and  post-change  products  for
SUPAC  related  changes,  or  with  different  strengths,  helps  assure  similarity  in  product
performance and signals bio inequivalence. Comparison of therapeutic performances of two
medicinal products containing the same      active substance is a critical means of assessing the
possibility of alternative using between the innovator and any essentially similar  medicinal
product. Dissolution  profiles of two products can be considered similar by virtue of
• Overall profile similarity, and 
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• Similarity at every dissolution sample time point.
A simple model independent approach uses a difference factor (f1) and a similarityfactor (f2)
to compare the dissolution profiles. The difference factor calculates the  percentage    
difference between the two curves at each time point and is   measurement of the relative
error between the two curves:
 where, n is the number of time points, Rt is the dissolution  value of the reference batch at time
t and Tt is the dissolution value of the test batch at time t.
       The similarity factor f2  is a logarithmic reciprocal square root transformation of the sum of
squared error and is a measurement of the similarity in the percent  dissolution between the two
curves.
  General procedure:
i. Determine the dissolution profile of two products (6 units each) of the test and 
reference products.
ii. Using the mean dissolution values from both the curves at each time interval,   
calculate the difference factor (f1) and similarity factor (f2) using the above       
equations.
iii. For curves to be considered similar, f1 values should be close to 0, and f2 values 
should be close to 100. Generally, f1 values upto 15 (0-15) and f2 values greater 
than 50 (50-100) ensures sameness or equivalence of the two curves.
The comparative dissolution study was performed to determine the similarity of dissolution
profiles  for  delayed  release  layer;  between  the  innovator  product  (PROTONIX) and  the
optimized formulation F5 . The results are tabulated in Table No: 28.      
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7.8. Stability studies:  
Stability of a drug has been defined as the ability of a particular formulation, in a specific
container,  to  remain  within  its  physical,  chemical,  therapeutics  and  toxicological
specifications. The purpose of stability testing is to provide evidence on how the quality of
a drug substance or  drug product  varies  with time under the influence of  a  variety of
environmental factors such as temperature, humidity and light, and to establish a retest for
the  drug  substance  or  a  shelf  life  for  the  drug  product  and  recommended  storage
conditions. The ICH guideline recommends the following storage conditions for stability
studies:
Table No - 16
S.No. Study Storage Condition
1. Long term 25°C±2°C / 60%RH±5%RH
2. Intermediate 30°C±2°C / 65%RH±5%RH
3. Accelerated 40°C±2°C / 75%RH±5%RH
As  per  ICH  guidelines,  the  samples  for  stability  analysis  must  be  exposed  to  an
environment  of  40˚C± 2˚C /  75% RH±5% RH for  a  period of  3  months.  As  per  the
standard  protocol the samples must be analysed at 0, 1, 2, and 3 months time points.
Accelerated  stability  studies  were  performed  for  the  final  Enteric  coated  tablets.  The
tablets were blister  packed and 5 pouches were placed into the stability chamber.  The
samples were analyzed at 0, 1, 2 and 3 months time points.
Test Performed:
i. Test for physical parameters (description, hardness, thickness, friability).
ii. Assay.
iii. In vitro Dissolution Study.
The results  of the stability studies are tabulated in  Table No:  29& 30. The data was
analyzed for any significant change in the values from the initial data.  
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8. RESULTS & DISCUSSION
8.1.  Preformulation Studies:
8.1.1. Evaluation of API
                                                    Table No- 17
S. No Test Limit Observation
1 Appearance White to off white crystalline
powder
Complies
 
2
                             Inf
ra red spectra
Sample IR spectrum should
comply with standard
IR spectrum
Sample  IR  spectrum
complies with standard
IR spectrum
 
3
 
Heavy metals
 
NMT 20 ppm
                                     
Complies
           
4
                             Te
st for Sodium
                                                
It gives reaction of sodium by
producing whiteprecipitate
                                    
Complies
           
5
                           Tota
l impurity
                                          NM
T 0.50 %
 
0.23%
 
6
 
Water content
(by KF %w/w)
 
5.9-6.9 %
 
6.69%
 
7
 
Assay 
 
99.0-101.0%
 
99.64%
Page 82
                                                                                         Results &  Discussion
Table No :18 - Solubility Studies
                             
Table No :19 - Micrometric Properties of API
API
Bulk
Density*
(g/ml )
Tapped
Density*
(g/ml )
Compressibility
Index (%)*
Hausner’s
Ratio*
Angle of
Repose*
(Degree)
Moisture
content
(%)
Pantoprazole
sodium 0.358±0.003 0.507±0.004 29.45±0.48 1.41±0.009 39.61±0.26
             
0.67%
Inference :
• The Bulk density of the powder was found to be 0.358gm/ml. 
• The Tapped density of the powder was found to be 0.507gm/ml. 
• The Compressibility Index was found to be 29.45 indicating poor flow properties.
• The Hausner’s ratio was found to be 1.41 and the value was indicating poor flow         
properties.
• The Angle of repose was obtained as 39.61°,  indicating poor flow of powder drug.
                        Based on the above results it was concluded that the drug is not suitable for
direct compression method due to fine particle size and poor flow characteristics.
8.1.2. Drug-Excipient compatibility studies
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S.No Solvent Quantity dissolved at 250c (mg/ml )
1 water 1023
2 Acetone 270
3 Chloroform 0.022
4 Di chloro methane 0.018
5 n- hexane 0.001
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a) Physical studies:
Table No : 20 -  Drug-Excipient Compatibility Study
S.N
o
           Composition details CommentsInitial
Storage
condition /
duration
(400C /
75%RH) /
30days
1 API ( Pantoprazole sodium )
     
White to off
white crystalline
powder
NCC Compatible
2  API+Mannitol Off White
crystalline
Powder
NCC Compatible
3 API + Crospovidone Off White
crystalline
Powder
NCC Compatible
4 API + Povidone + Sodium 
carbonate
Off White
crystalline
Powder
NCC Compatible
5 API + Microcrystaline 
cellulose
            ( avicel pH112)
Off White
crystalline
Powder
NCC Compatible
7 API +  Aerosil Off White
crystalline
Powder
 
NCC Compatible
8 AP I + Magnesium Stearate   Off White
crystalline
Powder
NCC Compatible
NCC- No Characteristic Change
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b) FT-IR studies
           The FT-IR spectra of the crude drug samples and the drug-excipient  mixtures are as 
           shown below.
Fig.6 - FT-IR spectra of Pantoprazole Sodium pure drug
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Fig. 7- FT-IR Spectra of Pantoprazole Sodium + Mannitol
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Fig .8 -  FT-IR Spectra oF Pantoprazole Sodium + Povidone +Sodium Carbonate
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                       Fig.9 - FT-IR Spectra of Pantoprazole Sodium + Crospovidone
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Fig.10-  FT-IR Spectra of Pantoprazole Sodium + MCC pH 112
                                                           
Page 89
                                                                                         Results &  Discussion
            
                                                    
Fig .12- FT-IR Spectra of Pantoprazole Sodium + Aerosil
Page 90
                                                                                         Results &  Discussion
       Fig .13- FT-IR Spectra of Pantoprazole Sodium +Magnesium Stearate
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Inference:   The  results  of  the  physical  compatibility studies  confirmed that  there  is  no
characteristic change was observed.
Chemical compatibility was studied with FT-IR.The  FT-IR spectrum of Pantoprazole sodium
with  excipients resembles  almost  with  the  spectra  of  authentic  sample  of  Pantoprazole
sodium, that shows the drug and excipients  used in formulation were compatible with each
other. based   on  the  above  proof,  further  formulations  of  Pantoprazole  sodium  with
combination of  excipients were done.
8.2. Formulation Trials Explanation
TRIAL I
In trial 1 die wall friction was observed to the tablets. in trial 1 the concentration of Mannitol
taken was 90.59 mg/unit.
Conclusion:
In  further trial  the concentration of Mannitol was decreased to 70 mg/unit. MCC pH 112
was included as diluent in the Extra granular portion of the formulation, because of its less
moisture content.  Aerosil  was also included to improve the flow property of the granules.
TRIAL  I I
 In trial 2 No defect was found during compression . and the core tablets were evaluated for
post compression parameters. and were submitted for analysis. All the parameters were found
satisfactory for the core tablet. coating was not given for the core tablets because of small
scale batch. Further trial has been taken as scale up of trail 2.
TRIAL  I I I
In trail 3 the tablets were compressed. And  the core tablets were evaluated, all the parameters
were found satisfactory. Core tablets were coated with 3 %w/w of seal coating solution with
an average weight  built up of 3%.these seal coated tablets were further coated with enteric
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coating solution with an average weight built up of 8%. Disintegration test was performed for
coated tablets, softening & colur change were observed on the  tablets in the Acid medium.
further weight gain from 8% to10% w/w. and D.T was performed, still softening of tablets
were observed in the acid media. further weight built up from 10% to12% w/w showed no
sign of softening  of the tablets in the acid media during 2 Hours  of the study period.
Remarks
Dissolution were Performed, in-vitro drug release was not complies with the USP limits.
Conclusion:
 So, further trial was taken by increasing the concentration of Crospovidone, to make the
tablets  disintegrate rapidly.
TRIAL   IV
In   trial  4 based on the above conclusion, the concentration of Mannitol is further decreased
to 65mg/unit and increasing the Crospovidone concentration to 13mg/unit.
         Initial dissolution test were  performed for the tablets, Coating layer around the tablet
showed sticking tendency to the bottom of the bowls, because of that reason  the drug was not
able to release completely from the tablet and drug release were found to be 68% at the end
of  45 min. which was not complies with the USP limits.
TRIAL   V
In trail 5 based on the above conclusion, the concentration of Mannitol is still decreased to
63mg/unit and increasing the Crospovidone concentration to 15mg/unit. diethyl phthalate is
replaced by triethyl citrate in the enteric coating part, to give better flexibility to the polymer.
           Dissolution test was performed and the acid release was found to be 1.6% at the end of
2 hrs.  which showed excellent physical  resistance to the acid medium compared to other
formulations. Altering the media to basic ( pH 6.8 phosphate buffer) and the  in-vitro drug
release was found to be 104% at the end of 45 min. which met the criteria outlined in this
study. And the tablets  were kept for stability studies & they are analysed periodicaly.
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Table No  21 -  Evaluation  of Pre compression Parameters For Granules
                                                      
Formulation
Code
Bulk
Density*
(g/ml )
Tapped
Density*
(g/ml )
Compressibility
Index (%)*
Hausner’s
Ratio*
Angle of 
Repose*
(Degree)
Moisture
content
(%)
F1 0.569±0.002 0.678±0.003 16.08±0.053 1.19±0.005 33.16±0.585 0.63%
F2 0.575±0.003 0.675±0.004 12.16±0.122 1.17±0.002 27.84±0.537 1.00%
F3 0.576±0.003 0.681±0.002 15.79±0.33 1.18±0.005 27.45±0.622 0.85%
F4 0.579±0.001 0.656±0.005 11.73±0.0499 1.26±0.005 26.27±0.448 1.05%
F5 0.574±0.001 0.648±0.001 11.29±0.125 1.12±0.001 24.51±0.333 0.88%
*All the values are mean ±SD, n=3
Inference: The result  of  flow properties  of  prepared granules  of  various formulations  of
Pantoprazole Sodium is given in TableNo: 21. Flow properties of the granules, resistance to
particle  movement  can  be  judged  from the  bulk  density,  tapped  density,  compressibility
index,  Hausner’s  ratio  and  angle  of  repose.  This  measurement  gives  qualitative  and
quantitative assessment of internal cohesive and frictional force under low levels of external
loading as might be applied in mixing and tabletting. The bulk density was found within the
range  of  0.569  to  0.579  g/ml.  The  tapped  density  was  found  within  the  range  of
0.64 to 0.68 g/cc.  using the density data,  Hausner’s  ratio and Compressibility index was
calculated. The Hausner’s ratio was found within the ranges of 1.12 to 1.19 which indicates
better flowability. The Compressibility index was found within the ranges of 11.29 to 16.08,
explaining good flow properties. The angle of repose was found using fixed funnel method,
which is within the ranges of  24.51 to31.16, indicating better flow properties.
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Table No: 22 -  Evaluation of Post-compression Parameters For  Un Coated  Tablets
Formulation
Code
Average
Weight
( mg )
Thickness
(mm)*
Friability
(%)*
Hardness*
(Kg/Cm2)
Disintegration
Time #
(Sec)
F1 151.30±1.12 2.75±0.03 0.048±0.001 4.5±0.12 1min50sec
±0.011
F2 151.34±0.67 3.12 ± 0.01 0.046±0.001 5.5±0.17
2min46sec
±0.056
F3 151.84±0.87 3.09±0.03 0.046±0.002 5.3±0.25 2 min7 Sec
±0.018
F4 150.64±1.23 3.34±0.02 0.046±0.002    5.4±0.24 2 min40 Sec
±0.057
F5 151.78±1.18 3.36±0.01 0.036±0.002    5.6±0.16 2 min38 Sec
±0.021
*All the values are mean ±SD, n=3
#All the values are mean ±SD, n=6
Table No: 23 - Evaluation of Post-compression Parameters for Enteric Coated Tablet
Formulation
Code
Average
Weight
( mg )
Thickness
(mm)*
Hardness*
(Kg/Cm2)
Disintegration
Time #
Drug Content
(%)*
F3 173.42±1.65 3.39 ± 0.03 6.2± 0.11 128 min 7 sec
±0.05
   101.37± 0.77
F4 171.0±1.56 3.45 ± 0.02 6.4± 0.12 126min13sec
±0.08
100.86±0.658
F5 172.36±1.32 3.68 ± 0.01 6.7± 0.11 125min63sec
±0.03
103.47±0.605
*All the values are mean ±SD, n=3
#All the values are mean ±SD, n=6
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  Inference :
• All  the  tablets  hardness  were  found  to  be  in  the  range  of  2-8  kg/cm2  in  all  the
formulations indicating  good mechanical strength.
• In all the formulations the friability value is less than 1 % giving an indication that
tablets formulated are mechanically stable during handling & transporting. 
• The thickness values were found to be with in the limits This may be due to the
adjustments of  upper and lower punch during compression process.
• The percentage weight variation  was with in the USP  limits.
• The  disintegration  of  different  formulations  complies  with  the  pharmacopeia
specifications.
• The drug content was known by performing assay and it was found to be 90-110%
and it was with in the limits .
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8.3.  Innovator Product Characterization :
Table No- 24
            Brand Name                  Protonix
           
            Label Claim Each protonix delayed release tablets contains 
45.1 mg of pantoprazole  sodium sesquihydrate     
equivalent to 40mg of pantoprazole .
       
          Manufacturer Wyeth pharmaceuticals inc., Philadelphia
   
        Physical Parameters
     Description
40mg yellow, oval      
biconvex shaped tablets 
plain on one side and     
imprinted with Protonix   
(brown ink) on other side.
       Thickness     4.5  mm
    
 
            Packaging details   30 tablet in blister strips
                        
                
                    Storage 
Store at room temperature between  59-860F     
(15-300C)
                   Shelf life
 
             3 years
               
                
             In active ingredient 
Calcium stearate, Crospovidone, ferric oxide,    
hypromellose,  mannitol, methacrylic acid        
copolymer, polysorbate 80, povidone, propylene 
glycol, sodium carbonate,  titanium dioxide, and 
triethyl citrate.
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Table No :25 -  Standard curve for Pantoprazole sodium in 0.1N Hcl
Fig.14 – Calibration curve for Pantoprazole Sodium in 0.1N HCl ( pH 1.2)
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Concentration (mcg/ml ) Absorbance at 305nm
0 0
1 0.041
2 0.078
3 0.116
4 0.153
5 0.189
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Table No :26 - Standard curve for Pantoprazole sodium in pH 6.8 Phosphate buffer
     
     Fig.14 – Calibration curve for Pantoprazole Sodium in pH 6.8 Phosphate buffer 
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Concentration (mcg/ml ) Absorbance at 288nm
0 0
5 0.135
10 0.268
15 0.411
20 0.545
25 0.681
30 0.809
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                 TableNo : 27 -  In-Vitro Dissolution Profile of Enteric Coated Tablets :
Page 100
 Dissolution
Media
 
Sampling
time
 
         
Cumulative% drug release in different trials 
           F3 F4 F5
Simulated gastric
fluid (0.1 HCL) 2 Hrs 2.57±0.534 2.08±0.483 1.6±0.501
Simulated
Intestinal Fluid
(6.8pH  Phosphate
buffer )
5 Min 4.89±0.474 2.44±0.554 4.34±0.333
10 Min 7.55±0.319 5.10 ±0.319 9.77±0.672
15 Min 38.79±0.486 29.03±0.338 40.37±0.589
20 Min 41.38±0.665 72.6±0.366 75.28±0.383
30 Min 52.91±0.653 64.97±0.662 87.19±0.226
45 Min 63.60±0.597 68.32 ±0.658 104.53±0.550
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Table No :28 –  Comparative Dissolution Profile Study with the Innovator Product
                                               
 Dissolution Media Sampling time
 
Cumulative % Drug Release 
f1 f2
          F5     Protonix           
                   Simulat
ed Gastric      fluid
(0.1 N HCL )
1.59 2.17
                   Simulat
ed intestinal fluid
( 6.8 PH Phosphate
buffer)
5 Min 4.34 4.67 4.2 81.7
10 Min 9.77 7.31
15 Min 40.37 38.11
20 Min 75.28 71.98
30 Min 87.19 88.95
Page 101
                                                                                         Results &  Discussion
45 Min 104.53 102.55
Fig. 16
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Inference:  The  f2 value  of  81.7  indicates  that  the  two products  are  similar  in  in  vitro
performance. 
8.4. Stability Studies
      Accelerated stability studies were carried out at 40˚C/75% RH for about 3 months in
stability chamber for formulation  F5.   
Table No - 29
Parameters
40˚C ± 2˚C / 75% RH ± 5% RH
Initial 1st month 2nd smonth 3rd month
Description * * * *
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Average weight
(mg)
172.36±1.32 172.38±1.14 172.42±1.67 172.43±1.37
Hardness (kg/cm2) 6.7±0.208 6.5±0.252 6.9±0.153 6.9±0.15
Thickness (mm) 3.68±0.02 3.66±0.015 3.68±0.03 3.68±0.015
Disintegration time
125min 63sec
± 0.036
127min 7sec
±  0.076
128min 16sec
±  0.043
127min 32 sec
± 0.052
Assay (%) 103.47 103.18 102.58 102.25
*Pale yellow,Round enteric -coated tablet
Inference: At  40˚C ± 2˚C / 75% RH ± 5% RH, for the first month and second month no
physical changes were observed. Average weight gradually increased every month, this may
be due to increase in moisture content. Assay data showed no significant variation during
stability studies.                                          
      Sampling 
Time points
         ( min )
                                          Storage condition
                              40˚C ± 2˚C / 75% RH ± 5% RH
Initial 1st month 2nd month 3rd month
                               SIMULATED GASTRIC FLUID (0.1 N HCL )  
           2 Hrs      1.59       1.67      1.79       1.56
                      SIMULATED INTESTINAL FLUID ( pH  6.8 PHOSPHATE BUFFER )
5 Min 4.34 3.33 ± 0.497 4.89 ± 0.467 3.99 ± 0.419
10 Min 9.77 10.19 ± 0.365 10.20 ± 0.36 11.08 ± 0.42
15 Min 40.37 41.62 ± 0.695 39.69 ± 0.674 40.58 ± 0.646
20 Min 75.28 74.40 ± 0.37 75.94 ± 0.72 73.29 ± 0.409
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30 Min 87.19 86.75 ± 0.659 86.31 ± 0.32 87.63 ± 0.59
45 Min 104.53 103.74 ± 0.442 105.42 ± 0.499 102.41 ± 0.173
Table No: 30 -   Stability Study Dissolution Data for Sample
                                                              
Fig. 17
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 Inference: Optimized formulation F5 ,was kept for stability studies and observed that drug
content, and in vitro dissolution profile are remained with out any significant changes, at the
end of 3rd month Hence it is concluded that the formulated Enteric coated tablets are stable
and the data obtained could be used to predict the shelf life of the product.
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9. CONCLUSION
    
 Preformulation studies has been performed to study the nature of API and compatibility of
API with excipients by physical observation and FT-IR studies. The results showed that there
was no interaction between API and  all the excipients selected.  
Delayed release enteric coated tablets of Pantoprazole sodium. were successfully formulated
by wet granulation method using the selected excipient  quantities.  The formulated tablets
were  evaluated  for  both  pre-compression  and  post-compression  parameters  as  per
requirements  of  standards.  And  The  results  were  complied  with  the  pharmacopoeia
specification.
From among the entire optimized batches, formulation F5 has been selected for  comparative
dissolution  profile  study  against  marketed  sample  PROTONIX.  since  it  provide  greater
protection to the core under acidic condition while at the same time show the fastest drug
release under intestinal pH. The results showed an f2 value of 81.7, thus it indicates that the
two products were similar in terms of in vitro drug release.
The most satisfactory formulation has been subjected to Accelerated stability studies as per
ICH guidelines. the results of stability studies showed no significant changes in the physical
parameters  of  the  tablets,  drug  content  and  in-vitro dissolution  pattern  until  the  end  of
3 months from initial values. Hence the formulation is considered stable and the data can be
employed for prediction of shelf life of the product.
Future scope
The present work may explore the following  aspects  in the future which may become a
valuable assets in the field of pharmaceutical science.
• Manufacture  Acid  labile  drug  into  formulations  as  cost  effective  &  stable
pharmaceutical compositon.
• The invitro studies can be extended to invivo studies by leading to a final conclusion
of a sucessful formulation which can be marketed there after.
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